Piperazine derivatives and process for the preparation thereof

ABSTRACT

The present invention relates to a novel compound of the general formula (I) and its pharmaceutically acceptable acid addition salt, and process for the preparation thereof, which have strong antimumor activities and very low toxicity.  
                 
 
     wherein R 1  and R 2  are independently hydrogen, C 1 -C 4  alkyl, C 1 -C 4  alkylcarboxyl, C 1 -C 4  alkylcarbonyl, C 1 -C 4  alkoxy, C 1 -C 4  hydroxyalkyl, C 1 -C 4  aminoalkyl or C 1 -C 4  hydroxyiminoalkyl, or R 1  and R 2  are fused to form C 3 -C 4  unsaturated ring;  
     R 3 , R 4 , R 5 , R 6  and R 7  are independently hydrogen, halogen, hydroxy, nitro, amino, C 1 -C 4  alkyl, C 1 -C 4  alkylcarboxyl, C 1 -C 4  alkylcarbonyl, C 1 -C 4  alkoxy or C 1 -C 4  thioalkoxy;  
     R 8  is C 1 -C 4  alkyl;  
     Y is oxygen, sulphur, amino, substituted amino or C 1 -C 4  thioalkyl;  
     Z is C 1 -C 4  alkoxy, C 1 -C 4  alkyl C 1 -C 4  alkylamino or C 1 -C 4  thioalkoxy;  
     X 1  and X 2  are independently carbon or nitrogen; and  
     —N═C— and —C═Y— may form a single bond or a double bond provided that if —N═C— forms a single bond, —C═Y— forms a double bond, and if —C═Y— forms a single bond, —N═C— forms a double bond and R 8  is nonexistent.

[0001] The present invention relates to a new piperazine derivative of the general formula (I) or its pharmaceutically acceptable acid addition salt, and process for the preparation thereof.

[0002] wherein R₁ and R₂ are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C_(l)-C₄ alkylcarbonyl, C₁-C₄ alkoxy, C₁-C₄ hydroxyalkyl, C₁-C₄ aminoalkyl or C₁-C₄ hydroxyiminoalkyl, or R₁ and R₂ are fused to form C₃-C₄ unsaturated ring;

[0003] R₃, R₄, R₅, R₆ and R₇ are independently hydrogen, halogen, hydroxy, nitro, amino, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy or C₁-C₄ thioalkoxy;

[0004] R₈ is C₁-C₄ alkyl;

[0005] Y is oxygen, sulphur, amino, substituted amino or C₁-C₄ thioalkyl;

[0006] Z is C₁-C₄ alkoxy, C₁-C₄ alkyl, C₁-C₄ alkylamino or C₁-C₄ thioalkoxy;

[0007] X₁ and X₂ are independently carbon or nitrogen; and

[0008] —N═C— and —C═Y— may formn a single bond or a double bond provided that if —N═C— forms a single bond, —C═Y— forms a double bond, and if —C═Y— forms a single bond, —N═C— forms a double bond and R₈ is nonexistent.

[0009] In the above definitions, C₁-C₄ alkyl means methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl or tert-butyl.

[0010] C₁-C₄ alkylcarboxyl means carboxyl esterified with a lower alkyl such as methylcarboxyl and ethylcarboxyl.

[0011] C₁-C₄ alkylcarbonyl means carbonyl ketonized with a lower alkyl such as methylcarbonyl and ethylcarbonyl.

[0012] C₁-C₄ alkoxy means methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or tert-butoxy.

[0013] C₁-C₄ thioalkoxy means methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio or tert-butylthio.

[0014] C₁-C₄ aminoalkyl means aminomethyl, aminoethyl, aminopropyl, aminobutyl or the like.

[0015] C₁-C₄ kydroxyalkyl means hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl or the like.

[0016] C₁-C₄ hydroxyiminoalkyl means C₁-C₄ alkyl substituted with hydroxyimino such as hydroxyiminoethyl.

[0017] Substituted amino means hydroxyamino, C₁-C₄ alkylamino, C₁-C₄ alkoxyamino or the like.

[0018] The present inventors had studied for a long time to find compounds having intensive antitumor activity. As a result, now we have finally found out the facts that the present compounds of the general formula (I) and acid addition salts thereof have not only prominent antitumor activities but very low toxicities.

[0019] Accordingly, the one object of the present invention is to provide the novel compounds of the general formula (I) and acid addition salts thereof having not only prominent antitumor activities but very low toxicities.

[0020] The other object of the present invention is to provide a process for the preparation of the compounds of general formula(I) and acid addition salts thereof.

[0021] The compounds of the present invention can be mixed with pharmaceutically acceptable vehicles by a known method to give pharmaceutical compositions and thus the pharmaceutical compositions can be used to prevent or treat with various kinds of tumors of human beings or mammals.

[0022] Therefore, another object of the present invention is to provide pharmaceutical compositions containing the compound of the general formula(I) or an acid addition salt thereof as an active ingredient.

[0023] Acids which can be reacted with the compounds of the general formula(I) to form acid addition salts are pharmaceutically acceptable inorganic or organic acids; for example, inorganic acids such as hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid; organic acids such as formic acid, acetic acid, propionic acid, succinic acid, citric acid, maleic acid, malonic acid, glycolic acid, lactic acid; amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, cysteine, cystine, asparaginic acid, glutamic acid, lysine, arginine, tyrosine, proline; sulfonic acids such as methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid; or the like.

[0024] Vehicles which can be used in the preparation of pharmaceutical compositions containing the compound of the general formula (I) as the active ingredient may include a sweetening agent, binding agent, dissolving agent, aids for dissolution, wetting agent, emulsifying agent, isotonic agent, adsorbent, degrading agent, antioxident, antiseptics, lubricating agent, filler, perfume or the like; such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid, stearin, magnesium stearate, calcium stearate, magnesium aluminum silicate, starch, gelatine, tragacanth gum, glycine, silica, alginic acid, sodium alginate, methyl cellulose, sodium carboxy methyl cellulose, agar, water, ethanol, polyethylenglycol, polyvinyl pyrrolidone, sodium chloride, potassium chloride, orange essence, strawberry essence, vanilla aroma or the like.

[0025] Daily dosage of the compound of the general formula (I) may be varied depending on age, sex of a patient, degree of disease, etc. and generally 1.0 mg to 5,000 mg per day may be administered one to several times.

[0026] The compounds of the general formula (I) according to the present invention wherein —N═C— forms a single bond and —C═Y— forms a double bond, may be prepared by the following scheme I.

[0027] wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, X₁, X₂, Y and Z are as defined above, and Lie is a conventional leaving group such as halogen, sulfonyl or the like.

[0028] The above process comprises reacting a compound of the general formula (2) with a —C(═Y)— group-providing agent in an organic solvent to obtain a compound of the general formula (3) and successively reacting the compound of the formula (3) with a compound of the general formula (4) to give the compound of the general formula (5). Then, the compound of the formula (5) may be reacted with an alkylating agent or an arylating agent in the presence of a base to give a compound of the general formula (Ia).

[0029] The —C(═X)-group-providing agent used in the above reaction may include 1,1-carbonyldiimidazole, 1,1-carbonylthiodiimidazole, phosgene, thiophosgene, carbonyldiphenoxide and phenylchloroformate, and it may be used in an amount of 1-1.5 equivalent, preferably 1-1.1 equivalent to the starting compound.

[0030] The reaction may be carried out in a conventional organic solvent such as, for example, tetrahydrofuran, dichloromethane, acetonitrile, chloroform and dimethylformamide.

[0031] And also the reaction is preferably carried out in the presence of a coupling agent such as a conventional inorganic or an organic base. Such conventional inorganic or organic bases used in the reaction may include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine and DBU.

[0032] The reaction may be carried out at a temperature between 3° C. and boiling point of the solvent used, preferably at 50° C.-100° C. and for 5-48 hours, preferably for 10-24 hours.

[0033] The reaction of the compound (3) with the compound (4) to give the compound (5) may be carried out in the presence of a conventional organic solvent at the temperature of 50-100° C. for 5-48 hours. The compound (4) may be used by 1-1.5 equivalent.

[0034] And also the reaction is preferably carried out in the presence of a conventional inorganic or organic base, such as sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine, DBU or the like.

[0035] Then, the compound of the formula (5) may be reacted with an alkylating agent or an arylating agent in the presence of a conventional organic or inorganic base to give a compound of the general formula (Ia).

[0036] The alkylating agent and arylating agent used in the above step may include C₁-C₈ alkylhalide, C₁-C₈ alkylsulfonate, substituted or unsubstituted C₃-C₈ cycloalkyl halide, arylhalide, and substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate.

[0037] C₁-C₈ alkyl halide means methyl chloride, methyl bromide, methyl iodide, ethyl chloride, ethyl bromide, ethyl iodide, propyl chloride, propyl bromide, propyl iodide, butyl chloride, butyl bromide, butyl iodide, pentyl chloride, pentyl bromide, pentyl iodide, bromo ehtylacetate or the like.

[0038] C_(l)-C₈ alkylsulfonate means methyl sulfonate, ethyl sulfonate, propyl sulfonate, butyl sulfonate, pentyl sulfonate or the like.

[0039] Substituted or unsubstituted C₃-C₈ cycloalkyl halides mean cyclopropyl chloride, cyclopropyl bromide, cyclopropyl iodide, cyclobutyl chloride, cyclobutyl bromide, cyclobutyl iodide, cyclopentyl chloride, cyclopentyl bromide, cyclopentyl iodide, cyclohexyl chloride, cyclohexyl bromide, cyclohexyl iodide, cyclopropyl methyl chloride, cyclopropyl methyl bromide, cyclopropyl methyl iodide, cyclobutyl methyl chloride, cyclobutyl methyl bromide, cyclobutyl methyl iodide, cyclopentyl methyl chloride, cyclopentyl methyl bromide, cyclopentyl methyl iodide, cyclohexyl methyl chloride, cyclohexyl methyl bromide, cyclohexyl methyl iodide, or the like.

[0040] Aryl halides may include benzyl chloride, benzyl bromide, benzyl iodide, benzoyl chloride, benzoyl bromide, benzoyl iodide, toluyl chloride, toluyl bromide and toluyl iodide.

[0041] Substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate may include cyclopropyl sulfonate, cyclobutyl sulfonate, cyclopentyl sulfonate, cyclohexyl sulfonate, cyclopropyl methyl sulfonate, cyclobutyl methyl sulfonate, cyclopentyl methyl sulfonate and cyclohexyl methyl sulfonate.

[0042] Aryl sulfonate may include benzyl sulfonate, benzoyl sulfonate, toluyl sulfonate, or the like.

[0043] The reaction may be carried out in a conventional organic solvent as such as, for example, tetrahydrofuran, dichloromethane, chloroform, dimethyl sulfoxide, acetonitrile and dimethylformamide.

[0044] The conventional inorganic or organic base used in above step may include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine and DBU.

[0045] In the above reaction process, if any acid material is formed, a basic material may be added as a scavenger in order to eliminate the acid material from the reaction phase. Such basic material may be alkali metal hydroxide, alkali earth metal hydroxide, alkali metal oxide, alkali earth metal oxide, alkali metal carbonate, alkali earth metal carbonate, alkali metal hydrogen carbonate, alkali earth metal hydrogen carbonate such as for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, calcium oxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium bicarbonate, sodium bicarbonate, calcium bicarbonate or the like, and organic amines.

[0046] The compounds of the general formula (2) and the formula (4) are known compounds, or may be prepared by a known method described in, for example, Farmaco(pavia) Ed, Sci., 18(8), 557-65(1963) or by a similar method thereto.

[0047] A compound of the general formula (I) wherein —C═Y— forms a single bond and —N═C— forms a double bond may be prepared by the following scheme II

[0048] wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, X₁, X₂, Y and Z are as defined above, and R′ is lower alkyl such as methyl and ethyl.

[0049] A compound of the general formula (II), which may be prepared by a known method, is reacted with an alkylating agent in the presence of a base to give a compound of the general formula (I′). Then, the compound of the formula (I′) is reacted with a substituted or unsubstitued amine in the presence of a base to give a compound of the general formula (Ib).

[0050] The reaction may be carried out at a temperature between 3° C. and boiling point of the solvent used, preferably at 50° C.-100° C. for 5-48 hours, preferably for 10-24 hours.

[0051] The alkylating agent may be used in an amount of 1-1.5 equivalent to the compound (II). The alkylating agent may include C₁-C₈ alkyl halide, C₁-C₈ alkylsulfonate, substituted or unsubstituted C₃-C₈ cycloalkyl halide, aryl halide and substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate.

[0052] The reaction may be carried out in a conventional organic solvent as described above.

[0053] The conventional inorganic or organic base as described above may be used in the above process.

[0054] The compound of the formula (I′) is reacted with a substituted or unsubstitued amine in the presence of a conventional base to give a compound of the general formula (Ib).

[0055] The reaction also may be preferably carried out in a conventional organic solvent as described above.

[0056] The conventional inorganic or organic base described above may be used in the above reaction step.

[0057] In the above reactions, if any acid material is formed, any basic material may be preferably added as a scavenger in order to eliminate the acid material from the reaction phase. Such basic material may be the organic or inorganic bases as described in the scheme I above.

[0058] The compound of the general formula (II) is a known compound, or may be prepared by a known method described in, for example, U.S. Pat. No. 5,780,472, PCT/KR97/00128 or by a similar method thereto.

[0059] Hereinafter the present invention will be described in more details with reference to following examples but it is not intended to limit the scope of the invention thereinto.

[0060] Compounds of the general formula (Ia) were prepared in following examples according to the above-mentioned process.

[0061] wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, X₁, X₂, Y and Z are as defined above. Ex R₁ R₂ R₃ R₄ R₅ R₆ R₇ R₈ X₁ X₂ Y Z 1 CH₃ CH₃ H H H H H H N N O OCH₃ 2 CH₃ CH₃ OCH₃ H H H H H N N O OCH₃ 3 CH₃ CH₃ H OCH₃ H OCH₃ H H N N O OCH₃ 4 CH₃ CH₃ Et H H H H H N N O OCH₃ 5 CH₃ CH₃ H H n-Bu H H H N N O OCH₃ 6 CH₃ CH₃ iPr H H H H H N N O OCH₃ 7 CH₃ CH₃ H CH₃ H CH₃ H H N N O OCH₃ 8 CH₃ CH₃ CH₃ CH₃ H CH₃ CH₃ H N N O OCH₃ 9 CH₃ CH₃ F H H H H H N N O OCH₃ 10 CH₃ CH₃ H Br H H H H N N O OCH₃ 11 CH₃ CH₃ H Cl H Cl H H N N O OCH₃ 12 CH₃ CH₃ H F H F H H N N O OCH₃ 13 CH₃ CH₃ H CF₃ H H H H N N O OCH₃ 14 CH₃ CH₃ SCH₃ H H H H H N N O OCH₃ 15 CH₃ CH₃ H NO₂ H NO₂ H H N N O OCH₃ 16 CH₃ CH₃ H NH₂ H NH₂ H H N N O OCH₃ 17 CH₃ CH₃ H H Ac H H H N N O OCH₃ 18 CH₃ CH₃ OCH₃ H H H H CH₃ N N O OCH₃ 19 CH₃ CH₃ H OCH₃ H OCH₃ H CH₃ N N O OCH₃ 20 CH₃ CH₃ H CH₃ H CH₃ H CH₃ N N O OCH₃ 21 CH₃ CH₃ H Cl H Cl H CH₃ N N O OCH₃ 22 CH₃ CH₃ H F H F H CH₃ N N O OCH₃ 23 CH₃ CH₃ SCH₃ H H H H CH₃ N N O OCH₃ 24 CH₃ CH₃ H NO₂ H NO₂ H CH₃ N N O OCH₃ 25 CH₃ CH₃ H NH₂ H NH₂ H CH₃ N N O OCH₃ 26 CH₃ CH₃ H OCH₃ H OCH₃ H Et N N O OCH₃ 27 CH₃ CH₃ H CH₃ H CH₃ H Et N N O OCH₃ 28 CH₃ CH₃ H OCH₃ H OCH₃ H H N N S OCH₃ 29 CH₃ CH₃ Et H H H H H N N S OCH₃ 30 CH₃ CH₃ H CH₃ H CH₃ H H N N S OCH₃ 31 CH₃ CH₃ H Br H H H H N N S OCH₃ 32 CH₃ CH₃ H Cl H Cl H H N N S OCH₃ 33 CH₃ CH₃ SCH₃ H H H H H N N S OCH₃ 34 Et Et H CH₃ H CH₃ H H N N O OCH₃ 35 Et Et H OCH₃ H OCH₃ H H N N O OCH₃ 36 CH═CH—CH═CH H H H H H H N N O OCH₃ 37 CH═CH—CH═CH OCH₃ H H H H H N N O OCH₃ 38 CH═CH—CH═CH H OCH₃ H OCH₃ H H N N O OCH₃ 39 CH═CH—CH═CH Et H H H H H N N O OCH₃ 40 CH═CH—CH═CH iPr H H H H H N N O OCH₃ 41 CH═CH—CH═CH H H nBu H H H N N O OCH₃ 42 CH═CH—CH═CH H CH₃ H CH₃ H H N N O OCH₃ 43 CH═CH—CH═CH CH₃ CH₃ H CH₃ CH₃ H N N O OCH₃ 44 CH═CH—CH═CH F H H H H H N N O OCH₃ 45 CH═CH—CH═CH H Br H H H H N N O OCH₃ 46 CH═CH—CH═CH H F H F H H N N O OCH₃ 47 CH═CH—CH═CH H CF₃ H H H H N N O OCH₃ 48 CH═CH—CH═CH H NO₂ H NO₂ H H N N O OCH₃ 49 CH═CH—CH═CH H NH₂ H NH₂ H H N N O OCH₃ 50 CH═CH—CH═CH H H Ac H H H N N O OCH₃ 51 CH═CH—CH═CH SCH₃ H H H H H N N O OCH₃ 52 CH═CH—CH═CH Ph H H H H H N N O OCH₃ 53 CH═CH—CH═CH H OCH₃ H OCH₃ H CH₃ N N O OCH₃ 54 CH═CH—CH═CH OCH₃ H H H H CH₃ N N O OCH₃ 55 CH═CH—CH═CH H CH₃ H CH₃ H CH₃ N N O OCH₃ 56 CH═CH—CH═CH H F H F H CH₃ N N O OCH₃ 57 CH═CH—CH═CH H NO₂ H NO₂ H CH₃ N N O OCH₃ 58 CH═CH—CH═CH H NH₂ H NH₂ H CH₃ N N O OCH₃ 59 CH═CH—CH═CH H OCH₃ H OCH₃ H Et N N O OCH₃ 60 CH═CH—CH═CH H CH₃ H CH₃ H Et N N O OCH₃ 61 CH═CH—CH═CH H Cl H Cl H Et N N O OCH₃ 62 CH═CH—CH═CH H OCH₃ H OCH₃ H iPr N N O OCH₃ 63 CH═CH—CH═CH OCH₃ H H H H H N N S OCH₃ 64 CH═CH—CH═CH F OCH₃ H OCH₃ H H N N S OCH₃ 65 CH═CH—CH═CH Et H H H H H N N S OCH₃ 66 CH═CH—CH═CH H CH₃ H CH₃ H H N N S OCH₃ 67 CH═CH—CH═CH H Br H H H H N N S OCH₃ 68 CH═CH—CH═CH H F H F H H N N S OCH₃ 69 CH═CH—CH═CH SCH₃ H H H H H N N S OCH₃ 70 CH═CH—CH═CH H H Ac H H H N N S OCH₃ 71 CH═CH—CH═CH H H nBu H H H N N S OCH₃ 72 CH═CH—CH═CH H OCH₃ H OCH₃ H H N N O OEt 73 CH═CH—CH═CH OEt H H H H H N N O OEt 74 CH═CH—CH═CH H CH₃ H CH₃ H H N N O OEt 75 CH═CH—CH═CH CH₃ CH₃ H H H H N N O OEt 76 CH═CH—CH═CH Et H H H H H N N O OEt 77 CH═CH—CH═CH H Cl H Cl H H N N O OEt 78 CH═CH—CH═CH H Br H H H H N N O OEt 79 CH═CH—CH═CH H F H F H H N N O OEt 80 CH═CH—CH═CH SCH₃ H H H H H N N O OEt 81 CH═CH—CH═CH H OCH₃ H OCH₃ H CH₃ N N O OEt 82 CH═CH—CH═CH H Cl H Cl H CH₃ N N O OEt 83 CH═CH—CH═CH H OCH₃ H OCH₃ H Et N N O OEt 84 CH═CH—CH═CH H Cl H Cl H Et N N O OEt 85 CH═CH—CH═CH H CH₃ H CH₃ H Et N N O OEt 86 CH═CH—CH═CH H CH₃ H CH₃ H H C C O OCH₃ 87 CH═CH—CH═CH H OCH₃ H OCH₃ H H C C O OCH₃ 88 CH═CH—CH═CH H F H F H H C C O OCH₃ 89 CH═CH—CH═CH H Cl H Cl H H C C O OCH₃ 90 CH═CH—CH═CH H CH₃ H CH₃ H CH₃ C C O OCH₃ 91 CH═CH—CH═CH H F H F H CH₃ C C O OCH₃ 92 CH═CH—CH═CH H Cl H Cl H CH₃ C C O OCH₃ 93 CH═CH—CH═CH H OCH₃ H OCH₃ H CH₃ C C O OCH₃ 94 CH═CH—CH═CH H OCH₃ H OCH₃ H Et C C O OCH₃ 95 CH═CH—CH═CH H CH₃ H CH₃ H Et C C O OCH₃

[0062] The compounds of the general formula (Ib) were prepared in the following examples according to the above-described process.

[0063] wherein, R₁, R₂, R₃, R₄, R₅, R₆, R₇, X, Y and Z are as defined above. Ex. R₁ R₂ R₃ R₄ R₅ R₆ R₇ X₁ X₂ Y Z 96 CH₃ CH₃ H H H H H C N NHOH OCH₃ 97 CH₃ CH₃ H H CH₃ H H C N NHOH OCH₃ 98 CH₃ CH₃ H H nBu H H C N NHOH OCH₃ 99 CH₃ CH₃ H CH₃ H CH₃ H C N NHOH OCH₃ 100 CH₃ CH₃ OCH₃ H H H H C N NHOH OCH₃ 104 CH₃ CH₃ H OCH₃ H OCH₃ H C N NHOH OCH₃ 102 CH₃ CH₃ H F H F H C N NHOH OCH₃ 103 CH₃ CH₃ H Cl H Cl H C N NHOH OCH₃ 104 CH₃ CH₃ H Br H H H C N NHOH OCH₃ 105 CH₃ CH₃ H NO₂ H NO₂ H C N NHOH OCH₃ 106 CH₃ CH₃ H

H

H C N NHOH OCH₃ 107 CH₃ CH₃ H

H

H C N NHOH OCH₃ 108 CH₃ Et OCH₃ H H H H C N NHOH OCH₃ 109 CH₃ Et H OCH₃ H OCH₃ H C N NHOH OCH₃ 110 CH₃ Et Et H H H H C N NHOH OCH₃ 111 CH₃ Et H H H H H C N NHOH OCH₃ 112 CH₃ Et SCH₃ H H H H C N NHOH OCH₃ 112 CH₃ Et H CH₃ H CH₃ H C N NHOH OCH₃ 114 CH₃ Et H F H F H C N NHOH OCH₃ 115 CH₃ Et H Cl H Cl H C N NHOH OCH₃ 116 CH₃ Et Ph H H H H C N NHOH OCH₃ 117 CH₃ Et H NO₂ H NO₂ H C N NHOH OCH₃ 118 CH₃

H OCH₃ H OCH₃ H C N NHOH OCH₃ 119 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 120 CH₃

H F H F H C N NHOH OCH₃ 121 CH₃

OCH₃ H H H H C N NHOH OCH₃ 122 CH₃

H H H H H C N NHOH OCH₃ 123 CH₃

H H CH₃ H H C N NHOH OCH₃ 124 CH₃

H Cl H H H C N NHOH OCH₃ 125 CH₃

H OCH₃ H OCH₃ H C N NHOH OCH₃ 126 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 127 CH₃

H F H F H C N NHOH OCH₃ 128 CH₃

OCH₃ H H H H C N NHOH OCH₃ 129 CH₃

H H H H H C N NHOH OCH₃ 130 CH₃

H H CH₃ H H C N NHOH OCH₃ 131 CH₃

H Cl H H H C N NHOH OCH₃ 132 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 133 CH₃

H OCH₃ H OCH₃ H C N NHOH OCH₃ 134 CH₃

H H H H H C N NHOH OCH₃ 135 CH₃

H H CH₃ H H C N NHOH OCH₃ 136 CH₃

H F H F H C N NHOH OCH₃ 137 CH₃

SCH₃ H H H H C N NHOH OCH₃ 138 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 139 CH₃

H OCH₃ H OCH₃ H C N NHOH OCH₃ 140 CH₃

H H H H H C N NHOH OCH₃ 141 CH₃

H H CH₃ H H C N NHOH OCH₃ 142 CH₃

H F H F H C N NHOH OCH₃ 143 CH₃

SCH₃ H H H H C N NHOH OCH₃ 144 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 145 CH₃

H F H F H C N NHOH OCH₃ 146 CH₃

H F H F H C N NHOH OCH₃ 147 CH₃

SCH₃ H H H H C N NHOH OCH₃ 148 CH₃

H NO₂ H NO₂ H C N NHOH OCH₃ 149 CH₃

H H CH₃ H H C N NHOH OCH₃ 150 CH₃

H CH₃ H CH₃ H C N NHOH OCH₃ 151 CH₃

H OCH₃ H OCH₃ H C N NHOH OCH₃ 152 CH₃

H F H F H C N NHOH OCH₃ 153 CH₃

SCH₃ H H H H C N NHOH OCH₃ 154 CH₃

H NO₂ H NO₂ H C N NHOH OCH₃ 155 CH₃

H Cl H Cl H C N NHOH OCH₃ 156 Et

H H CH₃ H H C N NHOH OCH₃ 157 Et

Et H H H H C N NHOH OCH₃ 158 Et

H CH₃ H CH₃ H C N NHOH OCH₃ 159 Et

H OCH₃ H OCH₃ H C N NHOH OCH₃ 160 Et

H Cl H Cl H C N NHOH OCH₃ 161 Et

SCH₃ H H H H C N NHOH OCH₃ 162 Et

H

H

H C N NHOH OCH₃ 163 Et

H F H F H C N NHOH OCH₃ 164 Et

H H CH₃ H H C N NHOH OCH₃ 165 Et

Et H H H H C N NHOH OCH₃ 166 Et

H CH₃ H CH₃ H C N NHOH OCH₃ 167 Et

H OCH₃ H OCH₃ H C N NHOH OCH₃ 168 Et

H Cl H Cl H C N NHOH OCH₃ 169 Et

SCH₃ H H H H C N NHOH OCH₃ 170 Et

H

H

H C N NHOH OCH₃ 171 Et

H F H F H C N NHOH OCH₃ 172 CH═CH—CH═CH H OCH₃ H OCH₃ H C N NHOH OCH₃ 173 CH═CH—CH═CH H CH₃ H CH₃ H C N NHOH OCH₃ 174 CH═CH—CH═CH H F H F H C N NHOH OCH₃ 175 CH═CH—CH═CH OCH₃ H H H H C N NHOH OCH₃ 176 CH═CH—CH═CH H Cl H H H C N NHOH OCH₃ 177 CH₃ CH₃ H H H H H C C NHOH OCH₃ 178 CH₃ CH₃ H H CH₃ H H C C NHOH OCH₃ 179 CH₃ CH₃ Et H H H H C C NHOH OCH₃ 180 CH₃ CH₃ H CH₃ H CH₃ H C C NHOH OCH₃ 181 CH₃ CH₃ H OCH₃ H OCH₃ H C C NHOH OCH₃ 182 CH₃ CH₃ H F H F H C C NHOH OCH₃ 183 CH₃ CH₃ H Cl H H H C C NHOH OCH₃ 184 CH₃ CH₃ H Br H H H C C NHOH OCH₃ 185 CH₃ CH₃ SCJH₃ H H H H C C NHOH OCH₃ 186 CH₃ CH₃ H H H H H C N NHOCH₃ OCH₃ 187 CH₃ CH₃ H H CH₃ H H C N NHOCH₃ OCH₃ 188 CH₃ CH₃ H CH₃ H CHJ₃ H C N NHOCH₃ OCH₃ 189 CH₃ CH₃ H OCH₃ H OCH₃ H C N NHOCH₃ OCH₃ 190 CH₃ CH₃ H F H F H C N NHOCH₃ OCH₃ 191 CH₃ CH₃ SCH₃ H H H H C N NHOCH₃ OCH₃ 192 CH₃ CH₃ H NO₂ H NO₂ H C N NHOCH₃ OCH₃ 193 CH₃ Et H Cl H Cl H C N NHOCH₃ OCH₃ 194 Et

H F H F H C N NHOCH₃ OCH₃ 195 Et

H

H

H C N NHOCH₃ OCH₃ 196 Et

H

H

H C N NHOCH₃ OCH₃ 197 CH₃ CH₃ H H CH₃ H H C C NHOCH₃ OCH₃ 198 CH₃ CH₃ H CH₃ H CH₃ H C C NHOCH₃ OCH₃ 199 CH₃ CH₃ H H H H H C N SCH₃ OCH₃ 200 CH₃ CH₃ H H CH₃ H H C N SCH₃ OCH₃ 201 CH₃ CH₃ H H nBu H H C N SCH₃ OCH₃ 202 CH₃ CH₃ H CH₃ H CH₃ H C N SCH₃ OCH₃ 203 CH₃ CH₃ OCH₃ H H H H C N SCH₃ OCH₃ 204 CH₃ CH₃ H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 205 CH₃ CH₃ H F H F H C N SCH₃ OCH₃ 206 CH₃ CH₃ H Cl H Cl H C N SCH₃ OCH₃ 207 CH₃ CH₃ H Br H H H C N SCH₃ OCH₃ 208 CH₃ CH₃ H NO₂ H NO₂ H C N SCH₃ OCH₃ 209 CH₃ CH₃ H

H

H C N SCH₃ OCH₃ 210 CH₃ Et H H H H H C N SCH₃ OCH₃ 211 CH₃ Et OCH₃ H H H H C N SCH₃ OCH₃ 212 CH₃ Et H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 213 CH₃ Et Et H H H H C N SCH₃ OCH₃ 214 CH₃ Et H CH₃ H CH₃ H C N SCH₃ OCH₃ 215 CH₃ Et H F H F H C N SCH₃ OCH₃ 216 CH₃ Et H Cl H Cl H C N SCH₃ OCH₃ 217 CH₃ Et Ph H H H H C N SCH₃ OCH₃ 218 CH₃ Et H NO₂ H NO₂ H C N SCH₃ OCH₃ 219 CH₃ Et SCH₃ H H H H C N SCH₃ OCH₃ 220 CH₃

H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 221 CH₃

H CH₃ H CH₃ H C N SCH₃ OCH₃ 222 CH₃

H F H F H C N SCH₃ OCH₃ 223 CH₃

OCH₃ H H H H C N SCH₃ OCH₃ 224 CH₃

H H H H H C N SCH₃ OCH₃ 225 CH₃

H H CH₃ H H C N SCH₃ OCH₃ 226 CH₃

H Cl H H H C N SCH₃ OCH₃ 227 CH₃

H CH₃ H CH₃ H C N SCH₃ OCH₃ 228 CH₃

H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 229 CH₃

H H H H H C N SCH₃ OCH₃ 230 CH₃

H H CH₃ H H C N SCH₃ OCH₃ 231 CH₃

H F H F H C N SCH₃ OCH₃ 232 CH₃

SCH₃ H H H H C N SCH₃ OCH₃ 233 Et

H H CH₃ H H C N SCH₃ OCH₃ 234 Et

Et H H H H C N SCH₃ OCH₃ 235 Et

H CH₃ H CH₃ H C N SCH₃ OCH₃ 236 Et

H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 237 Et

H Cl H Cl H C N SCH₃ OCH₃ 238 Et

H Cl H Cl H C N SCH₃ OCH₃ 239 Et

H

H

H C N SCH₃ OCH₃ 240 Et

H F F H C N SCH₃ OCH₃ 241 CH═CH—CH═CH H OCH₃ H OCH₃ H C N SCH₃ OCH₃ 242 CH═CH—CH═CH H CH₃ H CH₃ H C N SCH₃ OCH₃ 243 CH═CH—CH═CH H F H F H C N SCH₃ OCH₃ 244 CH═CH—CH═CH OCH₃ H H H H C N SCH₃ OCH₃ 245 CH═CH—CH═CH H Cl H H H C N SCH₃ OCH₃ 246 CH₃ CH₃ H H H H H C C SCH₃ OCH₃ 247 CH₃ CH₃ H H CH₃ H H C C SCH₃ OCH₃ 248 CH₃ CH₃ Et H H H H C C SCH₃ OCH₃ 249 CH₃ CH₃ H CH₃ H CH₃ H C C SCH₃ OCH₃ 250 CH₃ CH₃ H OCH₃ H OCH₃ H C C SCH₃ OCH₃ 251 CH₃ CH₃ H F H F H C C SCH₃ OCH₃ 252 CH₃ CH₃ H Cl H H H C C SCH₃ OCH₃ 253 CH₃ CH₃ H Br H H H C C SCH₃ OCH₃ 254 CH₃ CH₃ SCH₃ H H H H C C SCH₃ OCH₃

EXAMPLE 1)

[0064] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-phenylpiperazine

[0065] a) Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate:

[0066] 3-Amino-5,6-dimethyl-2-methoxypyrazine(1.00 g, 6.53 mmol) and phenylchloroformate (1.02 g, 6.53 mmol) were dissolved in dichloromethane and stirred at room temperature for 2 hours. The resulting mixture was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0067] yield: 98 %

[0068] m.p.: 101˜103° C.

[0069] b) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-phenyl piperazine:

[0070] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate (350 mg, 1.28 mmol) and 1-phenylpiperazine (208 mg, 1.28 mmol) were dissolved in anhydrous tetrahydrofuran and thereto DBU (195 mg, 1.28 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours and concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

[0071] yield: 78.5%

[0072] m.p.: 185˜187° C.

EXAMPLE 2)

[0073] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl] -4-(2-methoxyphenyl)piperazine

[0074] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0075] yield: 82.0%

[0076] m.p.: 184˜185° C.

EXAMPLE 3)

[0077] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0078] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0079] yield: 85.0%

[0080] m.p.: 136˜137° C.

EXAMPLE 4)

[0081] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

[0082] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0083] yield: 70.4%

[0084] m.p.: 197˜199° C.

EXAMPLE 5)

[0085] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(4-butylphenyl)piperazine

[0086] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(4-butylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0087] yield: 68.5%

[0088] m.p.: 121˜123° C.

EXAMPLE 6)

[0089] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-isopropylphenyl)piperazine

[0090] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-isopropylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0091] yield: 73.0%

[0092] m.p.: 165˜167° C.

EXAMPLE 7)

[0093] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0094] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0095] yield: 84.0%

[0096] m.p.: 162˜164° C.

EXAMPLE 8)

[0097] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethylphenyl)piperazine

[0098] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2,3,5,6,-tetramethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0099] yield: 65.5%

[0100] m.p.: 202˜204° C.

EXAMPLE 9)

[0101] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine

[0102] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0103] yield: 74.5%

[0104] m.p.: 170˜172° C.

EXAMPLE 10)

[0105] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine

[0106] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0107] yield: 70.0%

[0108] m.p.: 158˜160° C.

EXAMPLE 11)

[0109] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0110] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0111] yield: 80.5%

[0112] m.p.: 180˜181° C.

EXAMPLE 12)

[0113] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine

[0114] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0115] yield: 78.0%

[0116] m.p.: 153˜154° C.

EXAMPLE 13)

[0117] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3-trifluorotolyl)piperazine

[0118] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3-trifluorotolyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0119] yield: 69.5%

[0120] m.p.: 168˜170° C.

EXAMPLE 14)

[0121] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)piperazine

[0122] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0123] yield: 71.0%

[0124] m.p.: 202˜204° C.

EXAMPLE 15)

[0125] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine

[0126] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dinitrophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0127] yield: 64.5%

[0128] m.p.: 192˜194° C.

EXAMPLE 16)

[0129] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) aminocarbonyl]-4-(3,5-diaminophenyl)piperazine

[0130] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl )aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was dissolved in ethanol(30 ml) and thereto 10% palladium/carbon(10 mg) was added. The resulting mixture was hydrogenated for 4 hours, and then filtered to remove the 10% palladium/carbon. The filtrate was concentrated and purified by column chromatography to obtain the titled compound.

[0131] yield: 45.0%

[0132] m.p.: >100° C. (decomposed)

EXAMPLE 17)

[0133] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(4-acetylphenyl)piperazine

[0134] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(4-acetylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0135] Yield : 71.5%

[0136] m.p.: 166˜168° C.

EXAMPLE 18)

[0137] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4- (2-methoxyphenyl)piperazine

[0138] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine (200 mg, 0.54 mmol) was dissolved in dimethylformamide (15 ml) and thereto 60% sodium hydride (21.5 mg, 0.54 mmol) was added. The resulting mixture was stirred at room temperature for 15 minutes, and thereto methyl iodide (76.6 mg, 0.54 mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

[0139] yield: 92.5%

[0140] m.p.: 140˜142° C.

EXAMPLE 19)

[0141] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0142] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0143] yield: 90.5%

[0144] m.p.: 80˜82° C.

EXAMPLE 20)

[0145] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl] -4-(3,5-dimethylphenyl)piperazine

[0146] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0147] yield: 88.4%

[0148] m.p.: 94˜96° C.

EXAMPLE 21)

[0149] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-dichlorophenyl)piperazine

[0150] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0151] yield: 95.2%

[0152] m.p.: 97˜99° C.

EXAMPLE 22)

[0153] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-difluorophenyl)piperazine

[0154] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0155] yield: 94.0%

[0156] m.p.: 104˜106° C.

EXAMPLE 23)

[0157] 1-[(5,6-Dimethyl -2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4- (2-methylthiophenyl)piperazine

[0158] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0159] yield: 89.5%

[0160] m.p.: 133˜134° C.

EXAMPLE 24)

[0161] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-dinitrophenyl)piperazine

[0162] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0163] yield: 80.0%

[0164] m.p.: 133˜135° C.

EXAMPLE 25)

[0165] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-diaminophenyl)piperazine

[0166] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)N-methylaminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 18 to obtain the titled compound.

[0167] yield: 58.5%

[0168] m.p.: >100° C. (decomposed)

EXAMPLE 26)

[0169] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-ethylamino-carbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0170] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine (250 mg, 0.62 mmol) was dissolved in dimethylformamide (20 ml) and thereto 60% sodium hydride (24.9 mg, 0.62 mmol) was added. The mixture was stirred at room temperature for 15 minutes, and thereto methyl iodide (96.7 mg, 0.62 mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent used, and purified by column chromatography to obtain the titled compound.

[0171] yield: 89.5%

[0172] m.p.: 78˜80° C.

EXAMPLE 27)

[0173] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-ethylamino-carbonyl]-4-(3,5-dimethylphenyl)piperazine

[0174] 1-[(5,6-Dimethyl-2-methoxypyrazin -3-yl )aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 26 to obtain the titled compound.

[0175] yield: 92.0%

[0176] m.p.: 68˜70° C.

EXAMPLE 28)

[0177] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0178] a) Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate:

[0179] 3-Amino-5,6-dimethyl-2-methoxypyrazine (500 mg, 3.26 mmol) was dissolved in dichloromethane and thereto phenyl thiochloroformate (564 mg, 3.26 mmol) was slowly added. The mixture was stirred at room temperature for 24 hours, concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

[0180] yield: 78.5%

[0181] m.p.: 71˜73° C.

[0182] b) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl )piperazine:

[0183] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate (200 mg, 0.69 mmol) and 1-(3,5-dimethoxyphenyl)piperazine (154 mg, 0.69 mmol) were dissolved in anhydrous tetrahydrofuran (25 ml) and thereto DBU (105 mg, 0.69 mmol) was added. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0184] yield: 71.5%

[0185] m.p.: 183˜184° C.

EXAMPLE 29)

[0186] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl )aminothiocarbonyl]-4-(2-ethylphenyl)piperazine

[0187] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

[0188] yield: 64.0%

[0189] m.p.: 197˜199° C.

EXAMPLE 30)

[0190] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0191] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

[0192] yield: 68.4%

[0193] m.p.: 160˜162° C.

EXAMPLE 31)

[0194] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine

[0195] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

[0196] yield: 62.5%

[0197] m.p.: 136˜138° C.

EXAMPLE 32)

[0198] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0199] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

[0200] yield: 70.8%

[0201] m.p.: 182˜184° C.

EXAMPLE 33)

[0202] 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl] -4-(2-methylthiophenyl)piperazine

[0203] Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

[0204] yield: 61.4%

[0205] m.p.: 181˜183° C.

EXAMPLE 34)

[0206] 1-[(5,6-Dichloroethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0207] Phenyl N-(5,6-diethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0208] yield: 77.5%

[0209] m.p.: 118˜120° C.

EXAMPLE 35)

[0210] 1-[(5,6-Dichloroethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0211] Phenyl N-(5,6-diethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

[0212] yield: 78.9%

[0213] m.p.: 90˜92° C.

EXAMPLE 36)

[0214] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-phenylpiperazine

[0215] a) Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate:

[0216] 3-Amino-2-methoxyquinoxaline (1.00 g, 6.53 mmol) and phenylchloroformate (1.02 g, 6.53 mmol) were dissolved in dichloromethane and stirred at room temperature for 2 hours. The resulting mixture was concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound. yield: 75.5%

[0217] m.p.: 147˜149° C.

[0218] b) 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-phenylpiperazine:

[0219] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate (378 mg, 1.28 mmol) and 1-phenylpiperazine (208 mg, 1.28 mmol) were dissolved in anhydrous tetrahydrofuran and thereto DBU (195 mg, 1.28 mmol) was added. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

[0220] yield: 76.5%

[0221] m.p.: 156˜158° C.

EXAMPLE 37)

[0222] 1-[(2-Methoxyquinoxalin-3-yl )aminocarbonyl]-4-(2-methoxyphenyl) -piperazine

[0223] Phenyl N-(2-Methoxyquinoxalin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0224] yield: 72.4%

[0225] m.p.: 177˜178° C.

EXAMPLE 38)

[0226] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine

[0227] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-dimethoxy-phenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0228] yield: 81.2%

[0229] m.p.: 140˜141° C.

EXAMPLE 39)

[0230] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

[0231] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0232] yield: 75.0%

[0233] m.p.: 191˜193° C.

EXAMPLE 40)

[0234] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-isoprop-ylphenyl) piperazine

[0235] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-isopropylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0236] yield: 77.5%

[0237] m.p.: 147˜149° C.

EXAMPLE 41)

[0238] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(4-butylph-enyl)-piperazine

[0239] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(4-butylphenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0240] yield: 65.4%

[0241] m.p.: 124˜126° C.

EXAMPLE 42)

[0242] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine

[0243] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0244] yield: 79.3%

[0245] m.p.: 155˜157° C.

EXAMPLE 43)

[0246] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethyl-phenyl)piperazine

[0247] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0248] yield: 64.0%

[0249] m.p.: 237˜239° C.

EXAMPLE 44)

[0250] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-fluorop-henyl) piperazine

[0251] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-fluorophenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0252] yield: 67.5%

[0253] m.p.: 142˜144° C.

EXAMPLE 45)

[0254] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3-bromop-henyl) piperazine

[0255] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3-bromophenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0256] yield: 69.5%

[0257] m.p.: 148˜150° C.

EXAMPLE 46)

[0258] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluo-rophenyl) piperazine

[0259] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0260] yield: 74.5%

[0261] m.p.: 172˜173° C.

EXAMPLE 47)

[0262] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-trifluorotolyl) piperazine

[0263] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-trifluorotolyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0264] yield: 70.7%

[0265] m.p.: 132˜134° C.

EXAMPLE 48)

[0266] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl) piperazine

[0267] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-dinitrophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0268] yield: 54.5%

[0269] m.p.: 216˜218° C.

EXAMPLE 49)

[0270] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-diami-nophenyl) piperazine

[0271] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl) piperazine (200 mg, 0.44 mmol) was dissolved in ethanol (30 ml) and thereto 10% palladium/carbon (10 mg) was added. The mixture was hydrogenated for 4 hours, and then filtered to remove the 10% palladium/carbon. The filtrate was concentrated and purified by column chromatography to obtain the titled compound.

[0272] Yield : 42.5%

[0273] m.p.: >100° C. (decomposed)

EXAMPLE 50)

[0274] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(4-acetylp-henyl) piperazine

[0275] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(4-acetylphenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0276] yield: 71.0%

[0277] m.p.: 198˜200° C.

EXAMPLE 51)

[0278] 1-[(2-Methoxyquinoxalin-3-yl )aminocarbonyl]-4-(2-methylt-hiophenyl) piperazine

[0279] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0280] yield: 69.8%

[0281] m.p.: 180˜182° C.

EXAMPLE 52)

[0282] 1-[(2-Methoxyquinoxalin-3-yl)arninocarbonyl]-4-(2-biphen-yl)piperazine

[0283] Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-biphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0284] yield: 59.0%

[0285] m.p.:162˜165° C.

EXAMPLE 53) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0286] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl) piperazine (229 mg, 0.54 mmol) was dissolved in dimethylformamide (15 ml) and thereto 60% sodium hydride (21.5 mg, 0.54 mmol) was added. The mixture was stirred at room temperature for 15 minutes, and thereto ehtyl iodide (76.6 mg, 0.54 mmol) was, added. The mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0287] yield: 92.5%

[0288] m.p.: 143˜144° C.

EXAMPLE 54)

[0289] 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(2-methoxyphenyl)piperazine

[0290] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl) piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0291] yield: 83.8%

[0292] m.p.: 128˜130° C.

EXAMPLE 55)

[0293] 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0294] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0295] yield: 86.5%

[0296] m.p.: 142˜144° C.

EXAMPLE 56)

[0297] 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-difluorophenyl)piperazine

[0298] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0299] yield: 84.7%

[0300] m.p.: 197˜199° C.

EXAMPLE 57)

[0301] 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dinitrophenyl)piperazine

[0302] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl) piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0303] yield: 56.5%

[0304] m.p.: 197˜199° C.

EXAMPLE 58)

[0305] 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-diaminophenyl)piperazine

[0306] To 1-[(2-methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dinitrophenyl)piperazine dissolved in ethanol (30 ml), 10% palladium/carbon (10 mg) was added. The mixture was hydrogenated for 4 hours, and then filtered to remove the 10% palladium/carbon. The filtrate was concentrated and purified by column chromatography to obtain the titled compound.

[0307] Yield: 44.5%

[0308] m.p.: >100° C. (decomposed)

EXAMPLE 59)

[0309] 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0310] To 1-[(2-methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine (263 mg, 0.62 mmol) dissolved in dimethylformamide (20 ml), 60% sodium hydride (24.9 mg, 0.62 mmol) was added and stirred at room temperature for 15 minutes, and thereto methyl iodide (96.7 mg, 0.62 mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0311] yield: 85.4%

[0312] m.p.: 129˜130° C.

EXAMPLE 60)

[0313] 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0314] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine was reacted by the same way with the example 59 to obtain the titled compound.

[0315] yield: 87.6%

[0316] m.p.: 145˜147° C.

EXAMPLE 61)

[0317] 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0318] 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine were reacted by the same way with the example 59 to obtain the titled compound.

[0319] yield: 80.6%

[0320] m.p.: 146˜148° C.

EXAMPLE 62)

[0321] 1-[(2-Methoxyquinoxalin-3-yl) N-isopropylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0322] To 1-[(2-methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine (216 mg, 0.51 mmol) dissolved in dimethylformamide (20 ml), 60% sodium hydride (20.4 mg, 0.51 mmol) was added and stirred at room temperature for 15 minutes, and thereto propyl iodide (86.7 mg, 0.51 mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0323] yield: 82.0%

[0324] m.p.: 110˜112° C.

EXAMPLE 63)

[0325] 1-[(2-Methoxyquinoxalin-3-yl )aminothiocarbonyl]-4-(2-met-hoxyphenyl) piperazine

[0326] a) Phenyl N-(2-Methoxyquinoxalin-3-yl)thiocarbamate:

[0327] To 3-Amino-2-Methoxyquinoxaline (571 mg, 3.26 mmol) dissolved in dichloromethane, phenylthiochloroformate (564 mg, 3.26 mmol) were added slowly and stirred at room temperature for 24 hours. The resulting mixture was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0328] yield: 60.5%

[0329] m.p.: 160˜162° C.

[0330] b) 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl) piperazine:

[0331] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate (215 mg, 0.69 mmol) and 1-(2-methoxyphenyl)piperazine (154 mg, 0.69 mmol) were dissolved in anhydrous tetrahydrofuran (25 ml) and thereto DBU (105 mg, 0.69 mmol) was added. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0332] yield: 62.4%

[0333] m.p.: 177˜179° C.

EXAMPLE 64)

[0334] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxy-phenyl)piperazine

[0335] Phenyl N-(27methoxyquinoxalin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0336] yield: 64.5%

[0337] m.p.: 141˜143° C.

EXAMPLE 65)

[0338] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-ethylphenyl) piperazine

[0339] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0340] yield: 60.7%

[0341] m.p.: 141˜143° C.

EXAMPLE 66)

[0342] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-di-methyl-phenyl)piperazine

[0343] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0344] yield: 65.0%

[0345] m.p.: 193˜195° C.

EXAMPLE 67)

[0346] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3-bro-mophenyl) piperazine

[0347] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0348] yield: 57.5%

[0349] m.p.: 195˜197° C.

EXAMPLE 68)

[0350] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl) piperazine

[0351] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0352] yield: 59.0%

[0353] m.p.: 280˜281° C.

EXAMPLE 69)

[0354] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-methylthio-phenyl)piperazine

[0355] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0356] yield: 64.5%

[0357] m.p.: 148˜150° C.

EXAMPLE 70)

[0358] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(4-acetylphenyl) piperazine

[0359] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(4-acetylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0360] yield: 56.9%

[0361] m.p.: 235˜237° C.

EXAMPLE 71)

[0362] 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(4-but-ylphenyl) piperazine

[0363] Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(4-butylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

[0364] yield: 62.5%

[0365] m.p.: 163˜165° C.

EXAMPLE 72)

[0366] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine

[0367] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0368] yield: 74.7%

[0369] m.p.: 149˜150° C.

EXAMPLE 73)

[0370] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethoxyphenyl) piperazine

[0371] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(2-ethoxyphenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0372] yield: 76.5%

[0373] m.p.: 120˜122° C.

EXAMPLE 74)

[0374] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine

[0375] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0376] yield: 82.0%

[0377] m.p.: 152˜154° C.

EXAMPLE 75)

[0378] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl) piperazine

[0379] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0380] yield: 78.7%

[0381] m.p.: 108˜110° C.

EXAMPLE 76)

[0382] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

[0383] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0384] yield: 77.5%

[0385] m.p.: 152 154° C.

EXAMPLE 77)

[0386] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine

[0387] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0388] yield: 81.3%

[0389] m.p.: 157˜159° C.

EXAMPLE 78)

[0390] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine

[0391] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(3-bromophenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0392] yield: 80.6%

[0393] m.p.: 164 ˜166° C.

EXAMPLE 79)

[0394] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine

[0395] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0396] yield: 78.6%

[0397] m.p.: 146 148 ° C.

EXAMPLE 80)

[0398] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl) piperazine

[0399] Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

[0400] yield: 71.4%

[0401] m.p.: 139˜141° C.

EXAMPLE 81)

[0402] 1-[(2-Ethoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0403] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0404] yield: 92.8%

[0405] m.p.: 159˜161° C.

EXAMPLE 82)

[0406] 1-[(2-Ethoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0407] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine was reacted by the same way with the example 53 to obtain the titled compound.

[0408] yield: 94.5%

[0409] m.p.: 129˜131° C.

EXAMPLE 83)

[0410] 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0411] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 61 to obtain the titled compound.

[0412] yield: 82.8%

[0413] m.p.: 144˜146° C.

EXAMPLE 84)

[0414] 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0415] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine was reacted by the same way with the example 61 to obtain the titled compound.

[0416] yield: 80.7%

[0417] m.p.: 115˜117° C.

EXAMPLE 85)

[0418] 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0419] 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine was reacted by the same way with the example 61 to obtain the titled compound.

[0420] yield: 78.8%

[0421] m.p.: 142˜144 ° C.

EXAMPLE 86)

[0422] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine

[0423] a) Phenyl N-(2-methoxynaphth-3-yl)carbamate:

[0424] 3-Amino-2-methoxynaphthalene (1.13 g, 6.53 mmol) and phenylchloroformate (1.02 g, 6.53 mmol) were dissolved in dichloromethane. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0425] yield: 75.0%

[0426] m.p.: 105˜107° C.

[0427] b) 1-[(2-Methoxynaphth-3-yl) aminothiocarbonyl]-4-(3,5-dimethylphenyl-piperazine:

[0428] Phenyl N-(2-methoxynaphth-3-yl)carbamate (375 mg, 1.28 mmol) and 1-(3,5-dimethylphenyl)piperazine (208 mg, 1.28 mmol) were dissolved in anhydrous tetrahydrofuran (25 ml) and thereto DBU (195 mg, 1.28 mmol) was added, and then stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0429] yield: 72.0%

[0430] m.p.: 117˜119° C.

EXAMPLE 87)

[0431] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl) piperazine

[0432] Phenyl N-(2-methoxynaphth-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 86 to obtain the titled compound.

[0433] yield: 74.5%

[0434] m.p.: 191˜193° C.

EXAMPLE 88)

[0435] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine

[0436] Phenyl N-(2-methoxynaphth-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 86 to obtain the titled compound.

[0437] yield: 78.5%

[0438] m.p.: 160˜161° C.

EXAMPLE 89)

[0439] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl) piperazine

[0440] Phenyl N-(2-methoxynaphth-3-yl)carbamate and 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 86 to obtain the titled compound.

[0441] yield: 76.7%

[0442] m.p.: 182˜184 ° C.

EXAMPLE 90)

[0443] 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0444] To 1-[(2-methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine (210 mg, 0.54 mmol) dissolved in dimethylformamide (15 ml), 60% sodium hydride (21.5 mg, 0.54 mmol) was added, stirred at room temperature for 15 minutes, and thereto methyl iodide (76.6 mg, 0.54 mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0445] yield: 86.4%

[0446] m.p.: 134˜136° C.

EXAMPLE 91)

[0447] 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-difluorophenyl)piperazine

[0448] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)-piperazine was reacted by the same way with the example 90 to obtain the titled compound.

[0449] yield: 85.0%

[0450] m.p.: 115˜117° C.

EXAMPLE 92)

[0451] 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

[0452] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)-piperazine was reacted by the same way with the example 90 to obtain the titled compound.

[0453] yield: 89.8%

[0454] m.p.: 165˜167° C.

EXAMPLE 93)

[0455] 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0456] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 90 to obtain the titled compound.

[0457] yield: 92.5%

[0458] m.p.: 83˜85° C.

EXAMPLE 94)

[0459] 1-[(2-Methoxynaphth-3-yl)-N-ethylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

[0460] To 1-[(2-methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl) piperazine (210 mg, 0.54 mmol) dissolved in dimethylformamide (15 ml), 60% sodium hydride (21.5 mg, 0.54 mmol) was added, stirred at room temperature for 15 minutes, and thereto methyl iodide (84.2 mg, 0.54 mmol) was added. The mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0461] yield: 70.2%

EXAMPLE 95)

[0462] 1-[(2-Methoxynaphth-3-yl)-N-ethylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

[0463] 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 94 to obtain the titled compound.

[0464] yield: 85.0%

EXAMPLE 96)

[0465] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenylpiperazin-1-yl)carboxyimidamide

[0466] To methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl-piperazin-1-yl)iminothiorate (0.50 g, 1.35 mmol) dissolved in chloroform (30 ml), hydroxylamine hydrochlroride (0.25 g, 3.60 mmol) and triethylamine (0.41 g, 4.05 mmol) were added and stirred at room temperature for 15 hours, and then thereto water (30 ml) was added to stop reaction. The resulting mixture was extracted with methylene chloride. The organic layer was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0467] yield: 64.5%

[0468] m.p.: 173˜175° C.

EXAMPLE 97)

[0469] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

[0470] Methyl N-(5,6-dimethyl -2-methoxypyridin-3-yl)-[4-(4-methylphenyl )-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0471] yield: 55.2%

[0472] m.p.: 187˜189° C.

EXAMPLE 98)

[0473] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-butylphenyl)piperazin-1-yl]carboxyimidamide

[0474] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-butylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0475] yield: 60.1%

[0476] m.p.: 153˜155° C.

EXAMPLE 99)

[0477] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0478] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0479] yield: 67.5%

[0480] m.p.: 125˜128° C.

EXAMPLE 100)

[0481] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxy-phenyl)piperazin-1-yl]carboxyimidamide

[0482] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0483] yield: 62.0%

[0484] m.p.: 134˜136° C.

EXAMPLE 101)

[0485] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0486] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxy-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0487] yield: 57.2%

[0488] m.p.: 188˜190° C.

EXAMPLE 102)

[0489] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0490] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluoro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0491] yield: 60.7%

[0492] m.p.: 177˜178° C.

EXAMPLE 103)

[0493] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

[0494] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dichloro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0495] yield: 65.4%

[0496] m.p.: 185˜187° C.

EXAMPLE 104)

[0497] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromo-phenyl)piperazin-1-yl]carboxyimidamide

[0498] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromophenyl)-piperazine-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0499] yield: 68.1%

[0500] m.p.: 174˜176° C.

EXAMPLE 105)

[0501] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

[0502] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0503] yield: 45.2%

[0504] m.p.: 193˜195° C.

EXAMPLE 106)

[0505] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide

[0506] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0507] yield: 64.1%

[0508] m.p.: 166˜168° C.

EXAMPLE 107)

[0509] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-{4-[3,5-bis-(hydroxymethyl)phenyl]piperazin-1-yl}carboxyimidamide

[0510] To N-hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[(4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide (500 mg, 1.0 mmol) dissolved in tetrahydrofuran (20 ml), lithium aluminium hydride (57 mg, 1.5 mmol) were added slowly, and stirred at 20° C. for 1 hours, and then thereto water (0.5 ml) was added to stop reaction. The resulting mixture was concentrated under the reduced pressure to remove the solvent and extracted with methylene chloride with addition of water. The organic layer was dried with magnesium sulfate and purified by column chromatography to obtain the titled compound.

[0511] yield: 42.1%

[0512] m.p.: 184˜186° C.

EXAMPLE 108)

[0513] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]carboxyimidamide

[0514] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0515] yield: 69.4%

[0516] m.p.: 134˜135° C.

EXAMPLE 109)

[0517] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-di-methoxyphenyl)piperazin-1-yl]carboxyimidamide

[0518] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethox-yphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0519] yield: 68.2%

[0520] m.p.: 140˜142° C.

EXAMPLE 110)

[0521] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethyl-phenyl)piperazin-1-yl]carboxyimidamide

[0522] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphen-yl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0523] yield: 70.2%

[0524] m.p.: 157˜160° C.

EXAMPLE 111)

[0525] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl-piperazin- 1-yl)carboxyimidamide

[0526] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl-piperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0527] yield: 72.2%

[0528] m.p.: 178˜180° C.

EXAMPLE 112)

[0529] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyiridamide

[0530] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0531] yield: 69.3%

[0532] m.p.: 178˜179° C.

EXAMPLE 113)

[0533] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0534] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethyl-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0535] yield: 64.7%

[0536] m.p.: 155˜157° C.

EXAMPLE 114)

[0537] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-di-fluorophenyl)piperazin-1-yl]carboxyimidamide

[0538] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluoro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0539] yield: 51.8%

[0540] m.p.: 150˜152° C.

EXAMPLE 115)

[0541] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dichlorophenyl )piperazin-1-yl]carboxyimidamide

[0542] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dichloro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0543] yield: 72.2%

[0544] m.p.: 172˜174° C.

EXAMPLE 116)

[0545] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-biphenyl)piperazin-1-yl]carboxyimidamide

[0546] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-biphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0547] yield: 53.4%

[0548] m.p.: 195˜197° C.

EXAMPLE 117)

[0549] N-Hydroxy-N′-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

[0550] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0551] yield: 44.3%

[0552] m.p.: 193˜195° C.

EXAMPLE 118)

[0553] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidarnide

[0554] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0555] yield: 61.6%

[0556] m.p.: 192˜194° C.

EXAMPLE 119)

[0557] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimlidamide

[0558] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0559] yield: 63.0%

[0560] m.p.: 195˜197° C.

EXAMPLE 120)

[0561] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0562] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0563] yield: 57.4%

[0564] m.p.: 170˜172° C.

EXAMPLE 121)

[0565] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridine-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]carboxyimidamide

[0566] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0567] yield: 65.1%

[0568] m.p.: 176˜178° C.

EXAMPLE 122)

[0569] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)carboxyimidamide

[0570] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0571] yield: 69.5%

[0572] m.p.: 194˜196° C.

EXAMPLE 123)

[0573] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin- 1-yl]carboxyimidamide

[0574] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0575] yield: 73.2%

[0576] m.p.: 190˜192° C.

EXAMPLE 124)

[0577] N-Hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methylpyridine-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]carboxyimidamide

[0578] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0579] yield: 60.2%

[0580] m.p.: 91˜93° C.

EXAMPLE 125)

[0581] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin- 1-yl]carboxyimidamide

[0582] To N-hydroxy-N′-(5-methoxycarbonyl-2-methoxy-6-methyl-pyridin-3-yl)-[(4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide (300 mg, 0.65 mmol) dissolved in tetrahydrofuran (20 ml), lithium aluminium hydride (37 mg, 0.98 mmol) was added slowly and stirred at 20° C. for 1 hours. Then, water (0.5 ml) was added thereto to stop reaction. The resulting mixture was concentrated under the reduced pressure to remove the solvent, and extracted with methylene chloride with addition of water. The organic layer was dried with magnesium sulfate, and purified by column chromatography to obtain the titled compound.

[0583] yield: 45.8%

[0584] m.p.: 185˜187° C.

EXAMPLE 126)

[0585] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyr-idine-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0586] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0587] yield: 47.3%

[0588] m.p.: 127˜129° C.

EXAMPLE 127)

[0589] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0590] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0591] yield: 42.3%

[0592] m.p.: 179˜181° C.

EXAMPLE 128)

[0593] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]carboxyimid-amide

[0594] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0595] yield: 57.5%

[0596] m.p.: 129˜131° C.

EXAMPLE 129)

[0597] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyr-idine-3-yl)-(4-phenylpiperazin-1-yl)carboxyimidamide

[0598] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0599] yield: 61.6%

[0600] m.p.: 167˜169° C.

EXAMPLE 130)

[0601] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin- 1-yl]carboxyimidamide

[0602] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0603] yield: 66.7%

[0604] m.p.: 157˜159° C.

EXAMPLE 131)

[0605] N-Hydroxy-N′-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3-chlorophenyl)piperazin- 1-yl]carboxyimidamide

[0606] Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0607] yield: 56.2%

[0608] m.p.: 171˜173° C.

EXAMPLE 132)

[0609] N-Hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin- 1-yl]carboxyimidamide

[0610] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethyl-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0611] yield: 35.1%

[0612] m.p.: 174˜176° C.

EXAMPLE 133)

[0613] N-Hydroxy-N′-(5-acetyl -2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-di-methoxyphenyl)piperazin-1-yl]carboxyimidamide

[0614] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-di-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0615] yield: 32.4%

[0616] m.p.: 143˜145° C.

EXAMPLE 134)

[0617] N-Hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin- 1-yl)carboxyimidamide

[0618] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl )-(4-phenyl-piperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0619] yield: 40.5%

[0620] m.p.: 169˜170° C.

EXAMPLE 135)

[0621] N-Hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin- 1-yl]carboxyimidamide

[0622] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0623] yield: 55.2%

[0624] m.p.: 164˜166° C.

EXAMPLE 136)

[0625] N-Hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0626] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluoro-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0627] yield: 33.2%

[0628] m.p.: 184˜185° C.

EXAMPLE 137)

[0629] N-Hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0630] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0631] yield: 39.8%

[0632] m.p.: 178˜179° C.

EXAMPLE 138)

[0633] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0634] To N-hydroxy-N′-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[(4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide (150 mg, 0.36 mmol), ethanol (20 mil) and then sodium borohydride (17 mg, 0.45 mmol) were added slowly. The resulting mixture was stirred at 20° C. for 4 hours, concentrated under the reduced pressure to remove the solvent, and extracted with methylene chloride with addition of water. The organic layer was dried with magnesium sulfate and purified by column chromatography to obtain the titled compound.

[0635] yield: 75.6%

[0636] m.p.: 94˜96° C.

EXAMPLE 139)

[0637] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0638] Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 138 to obtain the titled compound.

[0639] yield: 65.6%

[0640] m.p.: 123˜125° C.

EXAMPLE 140)

[0641] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methyl-pyridin-3-yl]-(4-phenylpiperazin-1-yl)carboxyimidamide

[0642] Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 138 to obtain the titled compound.

[0643] yield: 72.3%

[0644] m.p.: 154 ˜155° C.

EXAMPLE 141)

[0645] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

[0646] Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 138 to obtain the titled compound.

[0647] yield: 62.1%

[0648] m.p.: 187˜189° C.

EXAMPLE 142)

[0649] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl] -[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0650] Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 138 to obtain the titled compound.

[0651] yield: 63.8%

[0652] m.p.: 156˜157° C.

EXAMPLE 143)

[0653] N-Hydroxy-N′-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0654] Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 138 to obtain the titled compound.

[0655] yield: 70.2%

[0656] m.p.: 162˜163° C.

EXAMPLE 144)

[0657] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methyl-pyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0658] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0659] yield: 23.2%

EXAMPLE 145)

[0660] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0661] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0662] yield: 35.6%

EXAMPLE 146)

[0663] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0664] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0665] yield: 33.3%

EXAMPLE 147)

[0666] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0667] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0668] yield: 30.2%

EXAMPLE 148)

[0669] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

[0670] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-ylliminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0671] yield: 29.5%

EXAMPLE 149)

[0672] N-Hydroxy-N′-[5-(1-hydroxyiminoethyl)-2-methoxy-6-me-thylpyridin-3 -yl]-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

[0673] Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0674] yield: 25.0%

EXAMPLE 150)

[0675] N-Hydroxy-N′-[5-(1-aaminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0676] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]imninothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0677] yield: 45.6%

EXAMPLE 151)

[0678] N-Hydroxy-N′-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0679] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0680] yield: 42.2%

EXAMPLE 152)

[0681] N-Hydroxy-N′-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0682] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0683] yield: 53.1%

EXAMPLE 153)

[0684] N-Hydroxy-N′-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0685] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0686] yield: 44.7%

EXAMPLE 154)

[0687] N-Hydroxy-N′-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

[0688] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dinitrophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0689] yield: 52.1%

EXAMPLE 155)

[0690] N-Hydroxy-N′-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-chlorophenyl)piperazin-1-yl]carboxyimidamide

[0691] Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0692] yield: 47.6%

EXAMPLE 156)

[0693] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

[0694] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0695] yield: 71.2%

[0696] m.p.: 176˜178° C.

EXAMPLE 157)

[0697] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamide

[0698] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0699] yield: 65.0%

[0700] m.p.: 182˜184° C.

EXAMPLE 158)

[0701] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0702] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0703] yield: 59.1%

[0704] m.p.: 152˜155° C.

EXAMPLE 159)

[0705] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0706] Methyl N-(6-ethyl-5-methoxycarbonyl -2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0707] yield: 55.6%

[0708] m.p.: 156˜157° C.

EXAMPLE 160)

[0709] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

[0710] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0711] yield: 54.4%

[0712] m.p.: 158˜160° C.

EXAMPLE 161)

[0713] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0714] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0715] yield: 50.1%

[0716] m.p.: 168˜170° C.

EXAMPLE 162)

[0717] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthalate-1-yl)piperazin-1-yl]carboxyimidamide

[0718] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin -3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0719] yield: 57.3%

[0720] m.p.: 101˜103° C.

EXAMPLE 163)

[0721] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimid-amide

[0722] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0723] yield: 45.0%

[0724] m.p.: 143˜145-C

EXAMPLE 164)

[0725] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

[0726] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0727] yield: 66.6%

[0728] m.p.: 170˜172° C.

EXAMPLE 165)

[0729] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin -3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamnide

[0730] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethyl-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0731] yield: 60.4%

[0732] m.p.: 185˜187° C.

EXAMPLE 166)

[0733] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0734] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0735] yield: 65.1%

[0736] m.p.: 75˜77° C.

EXAMPLE 167)

[0737] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0738] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0739] yield: 61.2%

[0740] m.p.: 67˜69° C.

EXAMPLE 168)

[0741] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl )-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

[0742] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0743] yield: 70.1%

[0744] m.p.: 75˜77° C.

EXAMPLE 169)

[0745] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

[0746] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0747] yield: 67.2%

[0748] m.p.: 163˜165° C.

EXAMPLE 170)

[0749] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl )-{4-[3,5-bis (hydroxymethyl)phenyl]piperazin-1-yl}carboxylmidamide

[0750] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-{4-[3,5-bis(hydroxymethyl)phenyl]piperazin-1-yl}iminothiolate was reacted by the same way with the example 125 to obtain the titled compound

[0751] yield: 59.4%

EXAMPLE 171)

[0752] N-Hydroxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

[0753] Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

[0754] yield: 48.7%

[0755] m.p.: 68˜70° C.

EXAMPLE 172)

[0756] N-Hydroxy-N′-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]carboxyimidamide

[0757] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0758] yield: 41.0%

[0759] m.p.: 215˜217° C.

EXAMPLE 173)

[0760] N-Hydroxy-N′-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]carboxyimidamide

[0761] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0762] yield: 44.2%

[0763] m.p.: 182˜184° C.

EXAMPLE 174)

[0764] N-Hydroxy-N′-(2-methoxyquinolin-3-yl)-[4-(3,5-difluoro-phenyl)-piperazin-1-yl]carboxyimidamide

[0765] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0766] yield: 38.1%

[0767] m.p.: 163˜165° C.

EXAMPLE 175)

[0768] N-Hydroxy-N′-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]carboxyimidamide

[0769] Methyl N-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0770] yield: 43.2%

[0771] m.p.: 210˜212° C.

EXAMPLE 176)

[0772] N-Hydroxy-N′-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]carboxyimidamide

[0773] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]-iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0774] yield: 45.2%

[0775] m.p.: 162˜164° C.

EXAMPLE 177)

[0776] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenyl-piperazin-1-yl)carboxyimidamide

[0777] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0778] yield: 62.7%

[0779] m.p.: 160˜162° C.

EXAMPLE 178)

[0780] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide

[0781] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0782] yield: 60.1%

[0783] m.p.: 181˜183° C.

EXAMPLE 179)

[0784] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethyl-phenyl)piperazin-1-yl]carboxyimidamide

[0785] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0786] yield: 65.4%

[0787] m.p.: 194˜196° C.

EXAMPLE 180)

[0788] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0789] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0790] yield: 64.1%

[0791] m.p.: 184˜186° C.

EXAMPLE 181)

[0792] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

[0793] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethoxy-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0794] yield: 65.5%

[0795] m.p.: 189˜191° C.

EXAMPLE 182)

[0796] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimnidamide

[0797] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluoro-phenyl)-piperazin-1-yl]imninothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0798] yield: 60.0%

[0799] m.p.: 179˜181° C.

EXAMPLE 183)

[0800] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chloro-phenyl)piperazin-1-yl]carboxyimidamide

[0801] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0802] yield: 58.7%

[0803] m.p.: 174˜176° C.

EXAMPLE 184)

[0804] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromo-phenyl)piperazin-1-yl]carboxyimidamide

[0805] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0806] yield: 61.2%

[0807] m.p.: 178˜180° C.

EXAMPLE 185)

[0808] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]carboxyimidamide

[0809] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methylthio-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

[0810] yield: 60.5%

[0811] m.p.: 194˜196° C.

EXAMPLE 186)

[0812] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenylpiperazin-1-yl)carboxyimidamide

[0813] To N-hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl-piperazin-1-yl)carboxyimidamide (0.5 g, 1.41 mmol) dissolved in dimethylformamide (15 ml), sodium hydride (60%, 57.8 mg, 1.45 mmol) and methyl iodide (0.20 g, 1.41 mmol) were added and stirred for 4 hours and then water (20 ml) was added thereto to stop reaction. The resulting mixture was extracted with ethylether. The organic layer was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

[0814] yield: 89.1%

EXAMPLE 187)

[0815] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide

[0816] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0817] yield: 92.2%

EXAMPLE 188)

[0818] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethyl-phenyl)piperazin-1-yl]carboxyimidamide

[0819] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0820] yield: 90.0%

EXAMPLE 189)

[0821] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-methoxyphenyl )piperazin-1-yl]carboxyimidamide

[0822] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-methoxyphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0823] yield: 92.2%

EXAMPLE 190)

[0824] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluoro-phenyl)piperazin-1-yl]carboxyimidamide

[0825] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl )-[4-(3,5-difluoro-phenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0826] yield: 85.2%

EXAMPLE 191)

[0827] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]carboxyimidamide

[0828] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methyl-thiophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0829] yield: 89.2%

EXAMPLE 192)

[0830] N-Methoxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitro-phenyl)piperazin-1-yl]carboxyimidamide

[0831] N-Hydroxy-N′-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitro-phenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0832] yield: 79.5%

EXAMPLE 193)

[0833] N-Methoxy-N′-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)-[4-(3,5-di-chlorophenyl)piperazin-1-yl]carboxylmidamide

[0834] N-Hydroxy-N′-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0835] yield: 84.2%

[0836] m.p.: 163˜165° C.

EXAMPLE 194)

[0837] N-Methoxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimid-amide

[0838] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0839] yield: 91.3%

EXAMPLE 195)

[0840] N-Methoxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide

[0841] N-Hydroxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0842] yield: 94.0%

EXAMPLE 196)

[0843] N-Methoxy-N′-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-{4-[3,5-bis(hydroxymethyl)phenyl-1-yl]piperazin-1-yl}carboxyimidamide

[0844] N-methoxy-N′-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0845] yield: 68.0%

EXAMPLE 197)

[0846] N-Methoxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide

[0847] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0848] yield: 86.7%

EXAMPLE 198)

[0849] N-Methoxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

[0850] N-Hydroxy-N′-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-di-methylphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

[0851] yield: 87.0%

EXAMPLE 199)

[0852] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenylpiperazin-1-yl)-iminothiolate

[0853] To 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-phenyl-piperazine (0.5 g, 1.40 mmol) dissolved in dimethylformamide (15 ml), sodium hydride (60%, 56.1 mg, 1.40 mmol) and methyl iodide (0.20 g, 1.41 mmol) were added. The resulting mixture was stirred for 2 hours and then water (20 ml) was added thereto to stop reaction. The resulting mixture was purified by column chromatography to obtain the titled compound.

[0854] yield: 92.4%

EXAMPLE 200)

[0855] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-et-hylphenyl)-piperazin-1-yl]iminothiolate

[0856] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl) aminothiocarbonyl] -4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0857] yield: 95.2%

EXAMPLE 201)

[0858] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-butylphenyl)piperazin-1-yl]iminothiolate

[0859] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl] -4-(4-n-butylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0860] yield: 93.4%

EXAMPLE 202)

[0861] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]liminothiolate

[0862] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl] -4-(3,5-di-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0863] yield: 97.2%

EXAMPLE 203)

[0864] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate

[0865] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0866] yield: 97.4%

EXAMPLE 204)

[0867] Methyl N-(5.6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate

[0868] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl] -4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0869] yield: 95.2%

EXAMPLE 205)

[0870] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-fluorophenyl)-piperazin-1-yl]iminothiolate

[0871] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0872] yield: 90.1%

EXAMPLE 206)

[0873] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-chlorophenyl)-piperazin-1-yl]iminothiolate

[0874] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl] -4-(3,5-di-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0875] yield: 92.5%

EXAMPLE 207)

[0876] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate

[0877] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0878] yield: 89.5%

EXAMPLE 208)

[0879] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-nitrophenyl)-piperazin-1-yl]iminothiolate

[0880] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl] -4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0881] yield: 92.9%

EXAMPLE 209)

[0882] Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-ethylisophthal-1-yl)-piperazin-1-yl]iminothiolate

[0883] 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl )aminothiocarbonyl]-4-(3,5-diethylisophthal-1-yl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0884] yield: 92.9%

EXAMPLE 210)

[0885] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl)piperazin-1-yl]iminothiolate

[0886] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0887] yield: 92.2%

EXAMPLE 211)

[0888] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate

[0889] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0890] yield: 87.2%

EXAMPLE 212)

[0891] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate

[0892] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0893] yield: 92.4%

EXAMPLE 213)

[0894] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate

[0895] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0896] yield: 93.6%

EXAMPLE 214)

[0897] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

[0898] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0899] yield: 96.2%

EXAMPLE 215)

[0900] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate

[0901] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0902] yield: 92.5%

EXAMPLE 216)

[0903] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dichlorophenyl)-piperazin-1-yl]iminothiolate

[0904] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0905] yield: 93.2%

EXAMPLE 217)

[0906] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-phenylphenyl)piperazin-1-yl]iminothiolate

[0907] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-phenylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0908] yield: 91.4%

EXAMPLE 218)

[0909] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)-piperazin-1-yl]iminothiolate

[0910] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0911] yield: 94.2%

EXAMPLE 219)

[0912] Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

[0913] 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0914] yield: 90.5%

EXAMPLE 220)

[0915] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

[0916] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)amino-thiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0917] yield: 93.2%

EXAMPLE 221)

[0918] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

[0919] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)amino-thiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0920] yield: 92.9%

EXAMPLE 222)

[0921] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

[0922] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0923] yield: 88.5%

EXAMPLE 223)

[0924] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iiminothiolate

[0925] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0926] yield: 90.2%

EXAMPLE 224)

[0927] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl-piperazin-1-yl)iminothiolate

[0928] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0929] yield: 93.5%

EXAMPLE 225)

[0930] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]iminothiolate

[0931] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothi-ocarbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0932] yield: 97.5%

EXAMPLE 226)

[0933] Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-chloro-phenyl)piperazin-1-yl]iminothiolate

[0934] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(2-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0935] yield: 95.5%

EXAMPLE 227)

[0936] Methyl N-(2-methoxy-5-methylcarbonyl-6-methyl-pyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

[0937] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0938] yield: 96.2%

EXAMPLE 228)

[0939] Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

[0940] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0941] yield: 95.4%

EXAMPLE 229)

[0942] Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)iminothiolate

[0943] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0944] yield: 90.1%

EXAMPLE 230)

[0945] Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate

[0946] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0947] yield: 92.2%

EXAMPLE 231)

[0948] Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]liminothiolate

[0949] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0950] yield: 93.1%

EXAMPLE 232)

[0951] Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

[0952] 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0953] yield: 90.0%

EXAMPLE 233)

[0954] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate

[0955] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0956] yield: 91.1%

EXAMPLE 234)

[0957] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate

[0958] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0959] yield: 90.4%

EXAMPLE 235)

[0960] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

[0961] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0962] yield: 95.5%

EXAMPLE 236)

[0963] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

[0964] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0965] yield: 95.4%

EXAMPLE 237)

[0966] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate

[0967] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0968] yield: 90.5%

EXAMPLE 238)

[0969] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

[0970] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0971] yield: 92.0%

EXAMPLE 239)

[0972] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthalate-1-yl)piperazin-1-yl]iminothi-olate

[0973] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(3,5-diethylisophthalate-1-yl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0974] yield: 93.2%

EXAMPLE 240)

[0975] Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

[0976] 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0977] yield: 95.2%

EXAMPLE 241)

[0978] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphe-nyl)piperazin-1-yl]-iminothiolate

[0979] 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxy-phenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0980] yield: 90.3%

EXAMPLE 242)

[0981] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]-iminothiolate

[0982] 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethyl-phenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0983] yield: 91.1%

EXAMPLE 243)

[0984] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-difluoro-phenyl)piperazin-1-yl]iminothiolate

[0985] 1-[(2-Methoxyquinolin-3-yl )aminothiocarbonyl]-4-(3,5-difluorophenyl)-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0986] yield: 94.2%

EXAMPLE 244)

[0987] Methyl N-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate

[0988] 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0989] yield: 92.4%

EXAMPLE 245)

[0990] Methyl N-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)pi-perazine-1-yl]-iminothiolate

[0991] 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3-chlorophenyl)-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0992] yield: 90.3%

EXAMPLE 246)

[0993] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenyl-piperazin-1-yl)-iminothiolate

[0994] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-phenyl-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0995] yield: 95.4%

EXAMPLE 247)

[0996] Methyl N-(4,5-dimethyl-2 methoxyphenyl-1-yl)-[4-(4-methylphenyl)-piperazin-1-yl]iminothiolate

[0997] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[0998] yield: 94.4%

EXAMPLE 248)

[0999] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate

[1000] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1001] yield: 96.2%

EXAMPLE 249)

[1002] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-di-methylphenyl)-piperazin-1-yl]iminothiolate

[1003] 1-[(4,5-Di-methyl-2-methoxyphenyl-1-yl )aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1004] yield: 96.8%

EXAMPLE 250)

[1005] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethoxy-phenyl)piperazin-1-yl]iminothiolate

[1006] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1007] yield: 95.7%

EXAMPLE 251)

[1008] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate

[1009] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1010] yield: 90.4%

EXAMPLE 252)

[1011] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]iminothiolate

[1012] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1013] yield: 94.2%

EXAMPLE 253)

[1014] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate

[1015] 1-[(4,5-Di-methyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1016] yield: 94.4%

EXAMPLE 254)

[1017] Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methylthiophenyl)-piperazin-1-yl]iminothiolate

[1018] 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

[1019] yield: 93.5%

[1020] Physical data of the compounds prepared in the above examples are as follows

EXAMPLE 1

[1021]¹H NMR(CDCl₃): δδ2.37 (3H,s), 2.39 (3H,s), 3.27 (4H,t), 3.74 (4H,t), 3.97 (3H,s), 6.97 (2H,m), 7.31 (2H,t)

EXAMPLE 2

[1022]¹H NMR(CDCl₃) : δ2.36 (3H,s), 2.40 (3H,s), 3.13 (4H,t), 3.75 (4H,t), 3.89 (3H,s), 3.97 (3H,s), 6.95 (3H,m), 7.05 (2H,m)

EXAMPLE 3

[1023]¹H NMR(CDCl₃): δ2.37 (3H,s), 2.39 (3H,s), 3.25 (4H,t), 3.71 (4H,t), 3.79 (6H,s), 3.97 (3H,s), 6.10 (3H,m)

EXAMPLE 4

[1024]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.37 (3H,s), 2.41 (3H,s), 2.74 (2H,q), 2.94 (4H,t), 3.68 (4H,t), 3.97 (3H,s), 6.72 (1H,brs), 7.08 (2H,m), 7.19 (1H,t), 7.25 (1H,s)

EXAMPLE 5

[1025]¹H NMR(CDCl₃) : δ0.92 (3H,t), 1.35 (2H,m), 1.57 (2H,m), 2.37 (3H,s), 2.39 (3H,s), 2.56 (2H,t), 3.25 (4H,t), 3.78 (4H,t), 3.97 (3H,s), 6.95 (2H,brs), 7.14 (2H,m)

EXAMPLE 6

[1026]¹H NMR(CDCl₃) : δ1.23 (6H,d), 2.38 (3H,s), 2.42 (3H,s), 2.95 (4H,t), 3.53 (1H,m), 3.72 (4H,t), 3.98 (3H,s), 7.11 (1H,m), 7.29 (1H,m)

EXAMPLE 7

[1027]¹H NMR(CDCl₃) : δ2.30(6H,s), 2.37 (3H,s), 2.40 (3H,s), 3.25 (4H,t), 3.75 (4H,t), 3.97 (3H,s), 6.62 (3H,m)

EXAMPLE 8

[1028]¹H NMR(CDCl₃): δ2.21 (6H,s), 2.22 (6H,s), 2.38 (3H,s), 2.43 (3H,s), 3.17 (4H,t), 3.67 (4H,t), 4.00 (3H,s), 6.84 (1H,s)

EXAMPLE 9

[1029]¹H NMR(CDCl₃): δ2.37 (3H,s), 2.40 (3H,s), 3.14 (4H,t), 3.73 (4H,t), 3.98 (3H,s), 6.99 (2H,m), 7.07 (2H,m)

EXAMPLE 10

[1030]¹H NMR(CDCl₃): δ2.37 (3H,s), 2.39 (3H,s), 3.26 (4H,t), 3.70 (4H,t), 3.98 (3H,s), 6.85 (1H,m), 7.01 (1H,d), 7.05 (1H,s), 7.13 (1H,t)

EXAMPLE 11

[1031]¹H NMR(CDCl₃): δ2.37 (3H,s), 2.39 (3H,s), 3.27 (4H,t), 3.69 (4H,t), 3.98 (3H,s), 6.75 (2H,s), 6.84 (1H,s)

EXAMPLE 12

[1032]¹H NMR(CDCl₃) : δ2.37 (3H,s), 2.39 (3H,s), 3.27 (4H,t), 3.69 (4H,t), 3.97 (3H,s), 6.30 (1H,t), 6.37 (2H,d)

EXAMPLE 13

[1033]¹H NMR(CDCl₃) : δ2.38 (3H,s), 2.40 (3H,s), 3.31 (4H,s), 3.73 (4H,t), 3.98 (3H,s), 7.09 (1H,d), 7.13 (2H,m), 7.38 (1H,t)

EXAMPLE 14

[1034]¹H NMR(CDCl₃): δ2.38 (3H,s), 2.42 (3H,s), 2.43 (3H,s), 3.05 (4H,t), 3.73 (4H,t), 3.99 (3H,s), 7.05 (1H,brs), 7.13 (1H,s)

EXAMPLE 15

[1035]¹H NMR(CDCl₃) : δ2.39 (3H,s), 2.45 (3H,s), 3.57 (4H,t), 3.88 (4H,t), 4.08 (3H,s), 7.98 (2H,s), 8.45 (1H,s)

EXAMPLE 16

[1036]¹H NMR(CDCl₃) : δ2.38 (3H,s), 2.40 (3H,s), 3.26 (4H,t), 3.70 (4H,t), 3.98 (3H,s), 6.35 (1H,s), 6.42 (2H,s)

EXAMPLE 17

[1037]¹H NMR(CDCl₃) : δ2.38 (3H,s), 2.40 (3H,s), 2.54 (3H,s), 3.46 (4H,t), 3.74 (4H,t), 3.99 (3H,s), 6.88 (2H,d), 7.90 (2H,d)

EXAMPLE 18

[1038]¹H NMR(CDCl₃) : δ2.39 (3H,s), 2.40 (3H,s), 2.91 (4H,t), 3.22 (3H,s), 3.46 (4H,t), 3.85 (3H,s), 3.95 (3H,s), 6.89 (3H,m), 7.02 (1H,m)

EXAMPLE 19

[1039]¹H NMR(CDCl₃) : δ2.39 (3H,s), 2.40 (3H,s), 3.01 (4H,t), 3.21 (3H,s), 3.40 (4H,t), 3.75 (6H,s), 3.92 (3H,s), 6.03 (3H,s)

EXAMPLE 20

[1040]¹H NMR(CDCl₃) : δ2.26 (6H,s), 2.39 (3H,s), 2.40 (3H,s), 2.99 (4H,t), 3.22 (3H,s), 3.40 (4H,t), 3.93 (3H,s), 6.52 (3H,m)

EXAMPLE 21

[1041]¹H NMR(CDCl₃) : δ2.40 (3H,s), 2.41 (3H,s), 3.03 (4H,t), 3.21 (3H,s), 3.38 (4H,t), 3.93 (3H,s), 6.68 (2H,s), 6.81 (1H,s)

EXAMPLE 22

[1042]¹H NMR(CDCl₃) : δ2.40 (3H,s), 2.41 (3H,s), 3.03 (4H,t), 3.21 (3H,s), 3.39 (4H,t), 3.93 (3H,s), 6.27 (3H,m)

EXAMPLE 23

[1043]¹H NMR(CDCl₃) : δ2.40 (9H,s), 2.87 (4H,t), 3.22 (3H,s), 3.46 (4H,t), 3.96 (3H,s), 7.02 (1H,brs), 7.11 (3H,s)

EXAMPLE 24

[1044]¹H NMR(CDCl₃) : δ2.43 (6H,s), 3.24 (3H,s), 3.27 (4H,t), 3.45 (4H,t), 3.95 (3H,s), 7.89 (2H,d), 8.40 (1H,s)

EXAMPLE 25

[1045]¹H NMR(CDCl₃) : δ2.38 (3H,s), 2.39 (3H,s), 2.95 (4H,t), 3.21 (3H,s), 3.37 (4H,t), 3.92 (3H,s), 5.62 (1H,s), 5.65 (2H,s)

EXAMPLE 26

[1046]¹H NMR(CDCl₃) : δ1.65 (3H,t), 2.39 (3H,s), 2.40 (3H,s), 2.96 (4H,t), 3.35 (4H,t), 3.74 (2H,q), 3.75 (6H,s), 3.92 (3H,s), 6.02 (3H,s)

EXAMPLE 27

[1047]¹H NMR(CDCl₃) : δ1.17 (3H,t), 2.25 (6H,s), 2.39 (3H,s), 2.40 (3H,s), 2.95 (4H,t), 3.36 (4H,t), 3.74 (2H,q), 3.92 (3H,s), 6.50 (3H,m)

EXAMPLE 28

[1048]¹H NMR(CDCl₃) : δ2.32 (3H,s), 2.34 (3H,s), 3.34 (4H,t), 3.78 (6H,s), 3.98 (3H,s), 4.07 (4H,t), 6.12 (3H,m)

EXAMPLE 29

[1049]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.35 (3H,s), 2.37 (3H,s), 2.74 (2H,q), 3.02 (4H,t), 3.97 (3H,s), 4.02 (4H,t), 7.09 (2H,q), 7.19 (1H,t), 7.55 (1H,s)

EXAMPLE 30

[1050]¹H NMR(CDCl₃) : δ2.29 (6H,s), 2.32 (3H,s), 2.35 (3H,s), 3.31 (4H,t), 3.98 (3H,s), 4.04 (4H,t), 6.59 (3H,brs)

EXAMPLE 31

[1051]¹H NMR(CDCl₃) : δ2.32 (3H,s), 2.35 (3H,s), 3.33 (4H,t), 3.98 (3H,s), 4.06 (4H,t), 6.82 (1H,d), 7.01 (2H,m), 7.13 (1H,t)

EXAMPLE 32

[1052]¹H NMR(CDCl₃): δ2.44 (3H,s), 2.49 (3H,s), 3.48 (4H,t), 4.05 (3H,s), 4.25 (4H,t), 6.98 (3H,m)

EXAMPLE 33

[1053]¹H NMR(CDCl₃) : δ2.35 (3H,s), 2.36 (3H,s), 2.43 (3H,s), 3.12 (4H,t), 3.97 (3H,s), 4.05 (4H,t), 6.87 (1H,d), 7.05 (1H,brs), 7.13 (2H,m)

EXAMPLE 34

[1054]¹H NMR(CDCl₃): δ1.26 (6H,m), 2.30 (6H,s), 2.70 (2H,t), 2.78 (2H,t), 3.25 (4H,t), 3.74 (4H,t), 3.99 (3H,s), 6.65 (3H,m)

EXAMPLE 35

[1055]¹H NMR(CDCl₃) : δ1.24 (6H,m), 2.69 (2H,t), 2.78 (2H,t), 3.24 (4H,t), 3.71 (4H,t), 3.78 (6H,s), 3.98 (3H,s), 6.07 (1H,s), 6.11 (2H,brs)

EXAMPLE 36

[1056]¹H NMR(CDCl₃): δ3.34 (4H,t), 3.88 (4H,t), 4.15 (3H,s), 7.05 (3H,m), 7.35 (3H,m), 7.43 (2H,m), 7.70 (1H,brs)

EXAMPLE 37

[1057]¹H NMR(CDCl₃) : δ3.17 (4H,t), 3.83 (4H,t), 3.90 (3H,s), 4.16 (3H,s), 6.99 (4H,m), 7.49 (2H,m), 7.75 (2H,m)

EXAMPLE 38

[1058]¹H NMR(CDCl₃) : δ3.22 (4H,t), 3.30 (4H,t), 3.79 (6H,s), 4.11 (3H,s), 7.20 (1H,d), 7.33 (2H,m), 7.50 (2H,m), 7.62 (1H,d), 7.76 (1H,m), 7.83 (1H,m)

EXAMPLE 39

[1059]¹H NMR(CDCl₃) : δ1.28 (3H,t), 2.78 (2H,q), 3.02 (4H,t), 3.89 (4H,t), 4.15 (3H,s), 7.13 (2H,m), 7.21 (1H,t), 7.28 (1H,m), 7.43 (3H,m), 7.70 (1H,d)

EXAMPLE 40

[1060]¹H NMR(CDCl₃) : δ1.24 (6H,d), 2.98 (4H,t), 3.56 (1H,m), 3.82 (4H,t), 4.15 (3H,s), 7.16 (3H,m), 7.30 (1H,d), 7.43 (2H,brs), 7.69 (2H,d)

EXAMPLE 41

[1061]¹H NMR(CDCl₃): δ0.93 (3H,t), 1.35 (2H,m), 1.57 (2H,m), 2.56 (2H,t), 3.35 (4H,t), 3.88 (4H,t), 4.15 (3H,s), 7.19 (3H,brs), 7.43 (3H,brs), 7.70 (2H,brs)

EXAMPLE 42

[1062]¹H NMR(CDCl₃) : δ2.30 (6H,s), 3.26 (4H,t), 3.78 (4H,t), 4.14 (3H,s), 6.60 (3H,s), 7.30 (2H,m), 7.50 (1H,s), 7.55 (1H,m)

EXAMPLE 43

[1063]¹H NMR(CDCl₃): δ2.21 (6H,s), 2.34 (6H,s), 3.20 (4H,t), 3.83 (4H,t), 4.17 (3H,s), 6.85 (1H,s), 7.46 (2H,m), 7.61 (1H,brs), 7.72 (1H,d)

EXAMPLE 44

[1064]¹H NMR(CDCl₃): δ3.20 (4H,t), 3.91 (4H,t), 4.15 (3H,s), 7.07 (4H,m), 7.42 (3H,m), 7.70 (1H,d)

EXAMPLE 45

[1065]¹H NMR(CDCl₃) : δ3.30 (4H,t), 3.90 (4H,t), 4.16 (3H,s), 6.95 (1H,d), 7.05 (1H,d), 7.15 (2H,m), 7.42 (2H,m), 7.53 (1H,s), 7.69 (1H,d)

EXAMPLE 46

[1066]¹H NMR(CDCl₃): δ3.27 (4H,t), 3.78 (4H,t), 4.16 (3H,s), 6.39 (3H,m), 7.52 (2H,m), 7.74 (2H,m)

EXAMPLE 47

[1067]¹H NMR(CDC₃) : δ3.34 (4H,t), 3.90 (4H,t), 4.16 (3H,s), 7.15 (3H,m), 7.40 (3H,m), 7.52 (1H,brs), 7.70 (1H,d)

EXAMPLE 48

[1068]¹H NMR(CDCl₃) : δ3.55 (4H,t), 3.98 (4H,t), 4.19 (3H,s), 7.46 (3H,m), 7.73 (1H,m), 8.00 (2H,s), 8.44 (1H,s)

EXAMPLE 49

[1069]¹H NMR(CDCl₃) : δ3.25 (4H,t), 3.73 (4H,t), 4.13 (3H,s), 5.68 (1H,brs), 5.79 (2H,brs), 7.49 (2H,m), 7.74 (2H,m)

EXAMPLE 50

[1070]¹H NMR(CDCl₃): δ2.54 (3H,s), 3.49 (4H,t), 3.92 (4H,t), 4.16 (3H,s), 6.95 (2H,d), 7.43 (2H,m), 7.51 (1H,brs), 7.71 (1H,d), 7.92 (2H,d)

EXAMPLE 51

[1071]¹H NMR(CDCl₃) : δ2.47 (3H,s), 3.30 (4H,t), 4.04 (4H,t), 4.19 (3H,s), 7.20 (3H,brs), 7.47 (2H,m), 7.60 (2H,m), 7.76 (1H,m)

EXAMPLE 52

[1072]¹H NMR(CDCl₃) : δ2.92 (4H,t), 3.57 (4H,t), 4.11 (3H,s), 7.15 (1H,d), 7.12 (1H,t), 7.30 (4H,m), 7.41 (4H,m), 7.54 (1H,m), 7.64 (3H,m)

EXAMPLE 53

[1073]¹H NMR(CDCl₃): δ3.19 (4H,t), 3.38 (3H,s), 3.68 (4H,t), 3.78 (6H,s), 4.07 (3H,s), 6.09 (3H,brm), 7.50 (2H,m), 7.80 (2H,m)

EXAMPLE 54

[1074]¹H NMR(CDCl₃) : δ3.08 (4H,t), 3.39 (3H,s), 3.73 (4H,t), 3.88 (3H,s), 4.09 (3H,s), 6.92 (4H,m), 7.50 (2H,m), 7.80 (2H,m)

EXAMPLE 55

[1075]¹H NMR(CDCl₃): δ2.30 (6H,s), 3.19 (4H,t), 3.39 (3H,s), 3.70 (4H,t), 4.08 (3H,s), 6.59 (3H,brs), 7.52 (2H,s), 7.80 (2H,m)

EXAMPLE 56

[1076]¹H NMR(CDCl₃) : δ3.20 (4H,t), 3.39 (3H,s), 3.66 (4H,t), 4.07 (3H,s), 6.35 (3H,m), 7.52 (2H,m), 7.82 (2H,m)

EXAMPLE 57

[1077]¹H NMR(CDCl₃) : δ3.41 (3H,s), 3.43 (4H,t), 3.71 (4H,t), 4.09 (3H,s), 7.55 (2H,m), 7.79 (1H,m), 7.88 (1H,m), 7.96 (2H,s), 8.44 (1H,s)

EXAMPLE 58

[1078]¹H NMR(CDCl₃) : δ3.13 (4H,t), 3.37 (3H,s), 3.65 (4H,t), 3.94 (3H,s), 5.59 (2H,m), 5.61 (1H,s), 7.50 (2H,m), 7.77 (1H,m), 7.82 (1H,m)

EXAMPLE 59

[1079]¹H NMR(CDCl₃) : δ1.33 (3H,t), 3.15 (4H,t), 3.65 (4H,t), 3.77 (6H,s), 3.91 (2H,q), 4.08 (3H,s), 6.09 (3H,brs), 7.52 (2H,m), 7.80 (2H,m)

EXAMPLE 60

[1080]¹H NMR(CDCl₃): δ1.34 (3H,t), 2.28 (6H,s), 3.12 (4H,t), 3.62 (4H,t), 3.91 (2H,q), 4.08 (3H,s), 6.55 (3H,brs), 7.51 (2H,m), 7.80 (2H,m)

EXAMPLE 61

[1081]¹H NMR(CDCl₃): δ1.33 (3H,t), 3.15 (4H,t), 3.61 (4H,t), 3.91 (2H,q), 4.08 (3H,s), 6.77 (2H,s), 6.87 (1H,s), 7.53 (2H,m), 7.78 (1H,m), 7.85 (1H,m)

EXAMPLE 62

[1082]¹H NMR(CDCl₃): δ1.43 (6H,d), 2.98 (4H,t), 3.48 (4H,d), 3.74 (6H,s), 4.06 (3H,s), 4.71 (1H,m), 5.99 (2H,s), 6.01 (1H,s), 7.53 (2H,m), 7.77 (1H,m), 7.84 (1H,m)

EXAMPLE 63

[1083]¹H NMR(CDCl₃) : δ3.49 (4H,t), 3.96 (3H,s), 4.15 (3H,s), 4.31 (4H,t), 7.06 (3H,m), 7.44 (3H,m), 7.71 (2H,d)

EXAMPLE 64

[1084]¹H NMR(CDCl₃): δ3.40 (4H,tI, 3.80 (6H,s), 4.15 (3H,s), 4.30 (4H,t), 6.16 (3H,brs), 6.84 (1H,d), 7.23 (1H,t), 7.44 (2H,brs), 7.70 (1H,brs)

EXAMPLE 65

[1085]¹H NMR(CDCl₃) : δ1.27 (3H,t), 2.76 (2H,q), 3.05 (4H,t), 4.15 (3H,s), 4.39 (4H,t), 7.10 (2H,m), 7.19 (1H,s), 7.40 (3H,m), 7.75 (1H,m), 8.01 (1H,s)

EXAMPLE 66

[1086]¹H NMR(CDCl₃) : δ2.31 (6H,s), 3.36 (4H,t), 4.14 (3H,s), 4.38 (4H,t), 6.64 (3H,brs), 7.45 (2H,m), 7.72 (2H,m)

EXAMPLE 67

[1087]¹H NMR(CDCl₃) : δ3.34 (4H,t), 4.16 (3H,s), 4.38 (4H,t), 6.85 (1H,d), 7.01 (1H,d), 7.06 (1H,s), 7.15 (1H,m), 7.42 (3H,m), 7.68 (1H,brs)

EXAMPLE 68

[1088]¹H NMR(CDCl₃) : δ3.42 (4H,t), 4.16 (3H,s), 4.30 (4H,t), 6.39 (3H,m), 7.20 (1H,t), 7.43 (1H,m), 7.69 (2H,m)

EXAMPLE 69

[1089]¹H NMR(CDCl₃) : δ2.46 (3H,s), 3.20 (4H,t), 4.15 (3H,s), 4.30 (4H,t), 6.90 (1H,m), 7.15 (3H,m), 7.45 (1H,m), 7.65 (1H,t), 7.73 (1H,m), 8.01 (1H,d)

EXAMPLE 70

[1090]¹H NMR(CDCl₃): δ2.56 (3H,s), 3.60 (4H,t), 4.15 (3H,s), 4.30 (4H,t), 6.96 (2H,d), 7.44 (1H,m), 7.59 (1H,m), 7.74 (2H,m), 7.95 (2H,m)

EXAMPLE 71

[1091]¹H NMR(CDC₃): δ0.92(3H,t), 1.35 (2H,m), 1.57 (2H,m), 2.56 (2H, t), 3.34 (4H,t), 4.11 (4H,t), 4.19 (3H,s), 6.91 (2H,m), 7.14 (2H,m), 7.60 (1H,t), 7.68 (1H,t), 7.98 (1H,d), 8.02 (1H,d)

EXAMPLE 72

[1092]¹H NMR(CDCl₃): δ1.52 (3H,t), 3.32 (4H,t), 3.79 (6H,s), 3.80 (4H,t), 4.60 (2H,q), 6.14 (3H,m), 7.44 (2H,brs), 7.69 (2H,brs)

EXAMPLE 73

[1093]¹H NMR(CDCl₃): δ1.50 (3H,t), 3.26 (4H,t), 3.86 (4H,t), 4.11 (2H,q), 4.62 (2H,q), 6.95 (2H,m), 7.07 (1H,brs), 7.55 (3H,m), 7.80 (2H,m)

EXAMPLE 74

[1094]¹H NMR(CDCl₃): δ1.52 (3H,t), 2.30 (6H,s), 3.30 (4H,t), 3.80 (4H,t), 4.61 (2H,q), 6.62 (3H,brs), 7.48 (2H,m), 7.76 (2H,m)

EXAMPLE 75

[1095]¹H NMR(CDCl₃) : δ1.52 (3H,t), 2.27 (3H,s), 2.29 (3H,s), 2.98 (4H,t), 3.78 (4H,t), 4.60 (2H,q), 6.94 (2H,m), 7.10 (1H,m), 7.30 (1H,brs), 7.47 (2H,brs), 7.74 (1H,brs)

EXAMPLE 76

[1096]¹H NMR(CDCl₃) : δ1.28 (3H,t), 1.52 (3H,t), 2.79 (2H,q), 3.06 (4H,t), 3.89 (4H,t), 4.61 (2H,q), 7.14 (2H,m), 7.22 (1H,t), 7.28 (1H,d), 7.44 (2H,m), 7.69 (2H,m)

EXAMPLE 77

[1097]¹H NMR(CDCl₃) : δ1.54 (3H,t), 3.36 (4H,t), 3.91 (4H,t), 4.63 (2H,q), 6.88 (2H,s), 6.90 (1H,s), 7.47 (2H,m), 7.59 (1H,brs), 7.71 (1H,m)

EXAMPLE 78

[1098]¹H NMR(CDCl₃): δ1.52 (3H,t), 3.30 (4H,t), 3.83 (4H,t), 4.60 (2H,q), 6.90 (1H,d), 7.03 (1H,d), 7.10 (1H,s), 7.15 (1H,t), 7.43 (2H,brs), 7.69 (1H,brs)

EXAMPLE 79

[1099]¹H NMR(CDCl₃) : δ1.52 (3H,t), 3.33 (4H,t), 3.77 (4H,t), 3.78 (4H,t), 4.68 (2H,q), 6.31 (1H,t), 6.40 (2H,d), 7.47 (2H,m), 7.54 (1H,m), 7.72 (1H,t)

EXAMPLE 80

[1100]¹H NMR(CDCl₃): δ1.52 (3H,t), 2.44 (3H,s), 3.13 (4H,t), 3.89 (4H,t), 4.61 (2H,q), 7.15 (4H,brs), 7.45 (2H,m), 7.69 (2H,brm)

EXAMPLE 81

[1101]¹H NMR(CDCl₃): δ1.44 (3H,t), 3.22 (4H,t), 3.38 (3H,s), 3.71 (4H,t), 3.78 (6H,s), 4.53 (2H,q), 6.09 (1H,brs), 6.13 (2H,brs), 7.50 (2H,m), 7.75 (1H,m), 7.82 (1H,m)

EXAMPLE 82

[1102]¹H NMR(CDCl₃) : δ1.43 (3H,t), 3.22 (4H,t), 3.38 (3H,s), 3.66 (4H,t), 4.54 (2H,q), 6.76 (2H,s), 6.86 (1H,s), 7.51 (2H,m), 7.76 (1H,m), 7.83 (1H,m)

EXAMPLE 83

[1103]¹H NMR(CDCl₃) : δ1.34 (3H,t), 1.44 (3H,t), 3.15 (4H,t), 3.62 (4H,t), 3.77 (6H,s), 3.91 (2H,q), 4.53 (2H,q), 6.06 (3H,brs), 7.51 (2H,m), 7.75 (1H,m), 7.81 (1H,m)

EXAMPLE 84

[1104]¹H NMR(CDCl₃): δ1.33 (3H,t), 1.44 (3H,t), 3.16 (4H,t), 3.59 (4H,t), 3.91 (2H,q), 4.54 (2H,q), 6.74 (2H,s), 6.85 (1H,s), 7.52 (2H,m), 7.76 (1H,m), 7.82 (1H,m)

EXAMPLE 85

[1105]¹H NMR(CDCl₃) : δ1.34 (3H,t), 1.45 (3H,t), 2.28 (6H,s), 3.15 (4H,t), 3.63 (4H,t), 3.91 (2H,q), 4.53 (2H,q), 6.56 (3H,brs), 7.50 (2H,m), 7.75 (1H,d), 7.82 (1H,d)

EXAMPLE 86

[1106]¹H NMR(CDCl₃): δ2.30 (6H,s), 3.27 (4H,t), 3.73 (4H,t), 4.03 (3H,s), 6.60 (3H,brs), 7.13 (1H,s), 7.33 (2H,t), 7.45 (1H,s), 7.67 (1H,m), 7.75 (1H,m)

EXAMPLE 87

[1107]¹H NMR(CDCl₃): δ3.20 (4H,t), 3.40 (4H,t), 3.75 (6H,s), 3.99 (3H,s), 6.10 (3H,brs), 7.12 (1H,s), 7.31 (2H,t), 7.44 (1H,s), 7.65 (1H,m), 7.70 (1H,m)

EXAMPLE 88

[1108]¹H NMR(CDCl₃): δ3.32 (4H,t), 3.73 (4H,t), 4.03 (3H,s), 6.32 (1H,t), 6.41 (2H,d), 7.13 (1H,s), 7.34 (2H,t), 7.43 (1H,s), 7.67 (1H,m), 7.75 (1H,m)

EXAMPLE 89

[1109]¹H NMR(CDCl₃) : δ3.34 (4H,t), 3.77 (4H,t), 4.03 (3H,s), 6.84 (1H,m), 6.92 (2H,m), 7.13 (1H,s), 7.34 (2H,m), 7.43 (1H,s), 7.68 (1H,m), 7.75 (1H,m)

EXAMPLE 90

[1110]¹H NMR(CDCl₃) : δ2.20 (6H,s), 2.85 (4H,t), 3.18 (3H,s), 3.32 (4H,t), 3.99 (3H,s), 6.39 (2H,s), 6.47 (1H,s), 7.20 (1H,s), 7.35 (1H,t), 7.43 (1H,t), 7.53 (1H,s), 7.69 (1H,d), 7.73 (1H,d)

EXAMPLE 91

[1111]¹H NMR(CDCl₃): δ2.91 (4H,t), 3.18 (3H,s), 3.33 (4H,t), 4.00 (3H,s), 6.24 (3H,brm), 7.21 (1H,s), 7.37 (1H,t), 7.45 (1H,t), 7.53 (1H,s), 7.70 (1H,d), 7.74 (1H,d)

EXAMPLE 92

[1112]¹H NMR(CDCl₃) : δ3.03 (4H,t), 3.18 (3H,s), 3.52 (4H,t), 4.01 (3H,s), 6.82 (3H,brm), 7.12 (1H,brs), 7.37 (1H,m), 7.46 (1H,m), 7.56 (1H,m), 7.72 (2H,m)

EXAMPLE 93

[1113]¹H NMR(CDCl₃): δ2.88 (4H,t), 3.18 (3H,s), 3.33 (4H,t), 3.71 (6H,s), 3.99 (3H,s), 5.92 (2H,brs), 5.97 (1H,brs), 7.20 (1H,s), 7.36 (1H,t), 7.43 (1H,t), 7.52 (1H,s), 7.69 (1H,d), 7.73 (1H,d)

EXAMPLE 94

[1114]¹H NMR(CDCl₃): δ1.34 (3H,t), 2.21 (6H,s), 2.88 (4H,t), 3.32 (4H,t), 3.91 (2H,q), 3.99 (3H,s), 6.39 (2H,s), 6.47 (1H,s), 7.20 (1H,s), 7.35 (1H,t), 7.46 (1H,t), 7.56 (1H,s), 7.71 (1H,d), 7.73 (1H,d)

EXAMPLE 95

[1115]¹H NMR(CDCl₃) : δ1.35 (3H,t), 2.90 (4H,t), 3.33 (4H,t), 3.70 (6H,s), 3.92 (2H,q), 3.99 (3H,s), 5.92 (2H,brs), 5.97 (1H,brs), 7.25 (1H,s), 7.36 (1H,t), 7.43 (1H,t), 7.52 (1H,s), 7.72 (1H,d), 7.73 (1H,d)

EXAMPLE 96

[1116]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.33 (3H,s), 3.19 (4H,s), 3.20 (4H,s), 3.98 (3H,s), 6.84 (1H,s), 6.87 (1H,t), 6.93 (2H,d), 7.25 (1H,d), 7.55 (1H,s)

EXAMPLE 97

[1117]¹H NMR(CDCl₃) : δ2.13 (3H,s), 2.27 (3H,s), 2.32 (3H,s), 3.13 (4H,d), 3.19 (4H,d), 3.98 (3H,s), 6.81 (1H,s), 6.83 (2H,d), 7.07 (2H,d), 7.54 (1H,s)

EXAMPLE 98

[1118]¹H NMR(CDCl₃): δ0.91 (3H,t), 1.30 (2H,m), 1.54 (2H,m), 2.13 (3H,s), 2.32 (3H,s), 2.53 (2H,t), 3.14 (4H,d), 3.19 (4H,d), 3.98 (3H,s), 6.80 (1H,s), 6.85 (2H,d), 7.08 (2H,d), 7.55 (1H,s)

EXAMPLE 99

[1119]¹H NMR(CDCl₃): δ2.13 (3H,s), 2.27 (6H,s), 2.32 (3H,s), 3.12 (4H,s), 3.13 (4H,s), 3.89 (3H,s), 6.56 (3H,s), 6.81 (1H,s), 7.54 (1H,s)

EXAMPLE 100

[1120]¹H NMR(CDCl₃) : δ2.16 (3H,s), 2.33 (3H,s), 3.08 (4H,t), 3.25 (4H,t), 3.85 (3H,s), 3.98 (3H,s), 6.87 (1H,t), 6.93 (2H,d), 7.02 (1H,m), 7.57 (1H,s)

EXAMPLE 101

[1121]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.32 (3H,s), 3.17 (8H,s), 3.77 (6H,s), 3.98 (3H,s), 6.04 (1H,s), 6.08 (2H,s), 6.81 (1H,s), 7.53 (1H,s)

EXAMPLE 102

[1122]¹H NMR(CDCl₃) : δ2.15 (3H,s), 2.33 (3H,s), 3.17 (8H,s), 3.98 (3H,s), 6.28 (1H,t), 6.35 (2H,d), 6.78 (1H,s), 7.50 (1H,s)

EXAMPLE 103

[1123]¹H NMR(CDCl₃) : δ2.16 (3H,s), 2.39 (3H,s), 3.18 (4H,s), 3.20 (4H,s), 3.98 (3H,s), 6.69 (3H,s), 6.78 (1H,s), 7.45 (1H,s)

EXAMPLE 104

[1124]¹H NMR(CDCl₃) : δ2.15 (3H,s), 2.33 (3H,s), 3.18 (8H,s), 3.98 (3H,s), 6.78 (1H,s), 6.82 (1H,d), 6.97 (1H,d), 7.03 (1H,s), 7.11 (1H,t), 7.51 (1H,s)

EXAMPLE 105

[1125]¹H NMR(CDCl₃) : δ2.16 (3H,s), 2.34 (3H,s), 3.20 (4H,s), 3.37 (4H,s), 3.90 (3H,s), 6.78 (1H,s), 7.47 (1H,s), 7.97 (2H,s), 8.42 (1H,s)

EXAMPLE 106

[1126]¹H NMR(CDCl₃); δ1.40 (6H,t), 2.17 (3H,s), 2.30 (3H,s), 3.29 (4H,s), 3.33 (4H,s), 3.98 (3H,s), 4.38 (4H,q), 7.41 (1H,s), 7.72 (2H,s), 8.16 (1H,s)

EXAMPLE 107

[1127]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.33 (3H,s), 3.21 (8H,s), 3.98 (3H,s), 4.66 (4H,s), 6.82 (1H,s), 6.88 (3H,s), 7.52 (1H,s)

EXAMPLE 108

[1128]¹H NMR(CDCl₃) : δ1.19 (3H,t), 2.36 (3H,s), 2.52 (2H,q), 3.07 (4H,s), 3.30 (4H,s), 3.84 (3H,s), 3.97 (3H,s), 6.85-7.03 (5H,m), 7.51 (1H,s)

EXAMPLE 109

[1129]¹H NMR(CDCl₃) : δ1.14 (3H,t), 2.36 (3H,s), 2.50 (2H,q), 3.17 (8H,d), 3.77 (6H,s), 3.98 (3H,s), 6.04 (1H,s), 6.07 (2H,s), 6.80 (1H,s), 7.56 (1H,s)

EXAMPLE 110

[1130]¹H NMR(CDCl₃) : δ1.22 (6H,m), 2.36 (3H,s), 2.54 (2H,q), 2.68 (2H,q), 2.90 (4H,s), 3.20 (4H,s), 3.98 (3H,s), 6.80 (1H,s), 7.08 (2H,m), 7.17 (1H,t), 7.22 (1H,d), 7.62 (1H,s)

EXAMPLE 111

[1131]¹H NMR(CDCl₃) : δ1.14 (3H,t), 2.36 (3H,s), 2.50 (2H,q), 3.18 (4H,s), 3.25 (4H,s), 3.98 (3H,s), 6.89 (4H,m), 7.27 (2H,m), 7.52 (1H,s)

EXAMPLE 112

[1132]¹H NMR(CDCl₃): δ1.20 (3H,t), 2.36 (3H,s), 2.38 (3H,s), 2.54 (2H,q), 3.00 (4H,s), 3.27 (4H,s), 3.97 (3H,s), 7.00 (1H,brs) 7.01 (1H,s), 7.10 (3H,s), 7.55 (1H,s)

EXAMPLE 113

[1133]¹H NMR(CDCl₃): δ1.14 (3H,t), 2.27 (6H,s), 2.36 (3H,s), 2.49 (2H,q), 3.17 (4H,s), 3.18 (4H,s), 3.98 (3H,s), 6.55 (3H,s), 6.81 (1H,s), 7.57 (1H,s)

EXAMPLE 114

[1134]¹H NMR(CDCl₃): δ1.15 (3H,t), 2.36 (3H,s), 2.50 (2H,q), 3.17 (8H,s), 3.98 (3H,s), 6.28 (1H,t), 6.35 (2H,d), 6.65 (1H,brs), 6.78 (1H,s), 7.52 (1H,s)

EXAMPLE 115

[1135]¹H NMR(CDCl₃) : δ1.15 (3H,t), 2.36 (3H,s), 2.50 (2H,q), 3.17 (8H,s), 3.98 (3H,s), 6.17 (1H,brs), 6.74 (3H,m), 6.82 (1H,s), 7.51 (1H,s)

EXAMPLE 116

[1136]¹H NMR(CDCl₃) : δ1.15(3H,t), 2.32 (3H,s), 2.48 (2H,q), 2.84 (4H,s), 2.94 (4H,s), 3.94 (3H,s), 6.73 (1H,s), 7.00 (1H,s), 7.09 (1H,t), 7.24 (2H,m), 7.29 (1H,t), 7.35 (2H,t), 7.51 (1H,s), 7.58 (2H,d)

EXAMPLE 117

[1137]¹H NMR(CDCl₃): δ1.15 (3H,t), 2.37 (3H,s), 2.51 (2H,q), 3.28 (4H,s), 3.39 (4H,s), 3.98 (3H,s), 6.84 (1H,brs), 7.47 (1H,s), 7.96 (2H,s), 8.42 (1H,s)

EXAMPLE 118

[1138]¹H NMR(CDCl₃) : δ2.69 (3H,s), 3.20 (8H,s), 3.77 (6H,s), 3.80 (3H,s), 4.06 (3H,s), 6.04 (1H,s), 6.09 (2H,s), 6.93 (1H,s), 8.39 (1H,s)

EXAMPLE 119

[1139]¹H NMR(CDCl₃): δ2.28 (6H,s), 2.70 (3H,s), 3.20 (8H,s), 3.80 (3H,s), 4.06 (3H,s), 6.56 (3H,s), 6.94 (1H,s), 8.40 (1H,s)

EXAMPLE 120

[1140]¹H NMR(CDCl₃): δ2.69 (3H,s), 3.19 (4H,d), 3.22 (4H,d), 3.80 (3H,s), 4.07 (3H,s), 6.29 (1H,t), 6.36 (2H,d), 6.75 (1H,brs), 6.93 (1H,s), 8.36 (1H,s)

EXAMPLE 121

[1141]¹H NMR(CDCl₃) : δ2.70 (3H,s), 3.13 (4H,s), 3.28 (4H,s), 3.83 (3H,s), 3.86 (3H,s), 4.06 (3H,s), 6.94 (5H,m), 8.42 (1H,s)

EXAMPLE 122

[1142]¹H NMR(CDCl₃) : δ2.70 (3H,s), 3.23 (8H,s), 3.78 (3H,s), 4.07 (3H,s), 6.89 (1H,t), 6.94 (2H,d), 6.99 (1H,brs), 7.27 (2H,d), 8.38 (1H,s)

EXAMPLE 123

[1143]¹H NMR(CDCl₃): δ2.27 (3H,s), 2.69 (3H,s), 3.17 (4H,d), 3.22 (4H,d), 3.78 (3H,s), 4.06 (3H,s), 6.84 (2H,d), 6.98 (1H,brs), 7.09 (1H,d), 8.38 (1H,s)

EXAMPLE 124

[1144]¹H NMR(CDCl₃) : δ2.70 (3H,s), 3.22 (8H,s), 3.80 (3H,s), 4.06 (3H,s), 6.78 (1H,d), 6.84 (1H,d), 6.88(1 H,s), 6.98(1H,brs), 7.17 (1H,t), 8.35 (1H,s)

EXAMPLE 125

[1145]¹H NMR(CDCl₃) : δ2.39 (3H,s), 3.17 (8H,s), 3.76 (6H,s), 4.00 (3H,s), 4.59 (2H,s), 6.03 (1H,s), 6.07 (2H,d), 6.88 (1H,s), 7.79 (1H,s)

EXAMPLE 126

[1146]¹H NMR(CDCl₃) : δ2.27 (6H,s), 2.40 (3H,s), 3.18 (8H,s), 4.01 (3H,s), 4.59 (2H,s), 6.55 (3H,s), 6.87 (1H,s), 7.80 (2H,s)

EXAMPLE 127

[1147]¹H NMR(CDCl₃) : δ2.40 (3H,s), 3.19 (8H,s), 4.00 (3H,s), 4.61 (2H,s), 6.27 (1H,t), 6.35 (2H,d), 6.86 (1H,s), 7.79 (1H,s)

EXAMPLE 128

[1148]¹H NMR(CDCl₃) : δ2.40 (3H,s), 3.08 (4H,s), 3.31 (4H,s), 3.84 (3H,s), 3.99 (3H,s), 4.61 (2H,s), 6.92 (5H,m), 7.77 (1H,s)

EXAMPLE 129

[1149]¹H NMR(CDCl₃) : δ2.39 (3H,s), 3.20 (8H,d), 4.00 (3H,s), 4.58 (2H,s), 6.90 (4H,m), 7.27 (2H,d), 7.79 (1H,s)

EXAMPLE 130

[1150]¹H NMR(CDCl₃): δ2.17 (3H,s), 2.39 (3H,s), 3.13 (4H,d), 3.22 (4H,d), 3.99 (3H,s), 4.58 (2H,s), 6.82 (2H,d), 7.00 (1H,brs), 7.06 (2H,d), 7.78 (1H,s)

EXAMPLE 131

[1151]¹H NMR(CDCl₃): δ2.39 (3H,s), 3.19 (8H,d), 4.00 (3H,s), 4.60 (2H,s), 6.76 (1H,d), 6.82 (1H,d), 6.85 (1H,s), 6.95 (1H,brs), 7.16 (1H,t), 7.77 (1H,s)

EXAMPLE 132

[1152]¹H NMR(CDCl₃): δ2.27 (6H,s), 2.50 (3H,s), 2.64 (3H,s), 3.19 (8H,d), 4.07 (3H,s), 6.55 (2H,s), 6.56 (1H,s), 6.88 (1H,s), 7.39 (1H,brs), 8.19 (1H,s)

EXAMPLE 133

[1153]¹H NMR(CDCl₃) : δ2.50 (3H,s), 2.64 (3H,s), 3.16 (4H,s), 3.25 (4H,s), 3.76 (6H,s), 4.06 (3H,s), 6.05 (1H,s), 6.07 (2H,s), 7.05 (1H,brs), 8.13 (1H,s)

EXAMPLE 134

[1154]¹H NMR(CDCl₃) : δ2.50 (3H,s), 2.65 (3H,s), 3.20 (4H,s), 3.26 (4H,s), 4.06 (3H,s), 6.91 (4H,m), 7.27 (2H,m), 8.15 (1H,s)

EXAMPLE 135

[1155]¹H NMR(CDCl₃) : δ2.18 (3H,s), 2.42 (3H,s), 2.57 (3H,s), 3.15 (4H,s), 3.30 (4H,s), 4.07 (3H,s), 6.84 (2H,d), 7.07 (3H,d), 8.13 (1H,s)

EXAMPLE 136

[1156]¹H NMR(CDCl₃) : δ2.52 (3H,s), 2.66 (3H,s), 3.22 (4H,s), 3.28 (4H,s), 4.07 (3H,s), 6.30 (3H,m), 8.07 (1H,s)

EXAMPLE 137

[1157]¹H NMR(CDCl₃) : δ2.39 (3H,s), 2.58 (3H,s), 2.66 (3H,s), 3.04 (4H,s), 3.33 (4H,s), 4.07 (3H,s), 7.02 (1H,d), 7.10 (3H,s), 8.14 (1H,s)

EXAMPLE 138

[1158]¹H NMR(CDCl₃) : δ1.40 (3H,d), 2.26 (6H,s), 2.39 (3H,s), 3.19 (8H,s), 3.99 (3H,s), 5.04 (1H,q), 6.54 (3H,s), 6.86 (1H,s), 7.93 (1H,s)

EXAMPLE 139

[1159]¹H NMR(CDCl₃) δ1.40 (3H,d), 2.39 (3H,s), 3.20 (8H,m), 3.76 (6H,s), 3.99 (3H,s), 5.03 (1H,q), 6.03 (1H,s), 6.06 (2H,s), 7.04 (1H,brs), 7.89 (1H,s)

EXAMPLE 140

[1160]¹H NMR(CDCl₃) : δ1.40 (3H,d), 2.39 (3H,s), 3.19 (4H,m), 3.30 (4H,s), 3.97 (3H,s), 5.08 (1H,q), 6.89 (3H,m), 7.24 (2H,m), 7.87 (1H,s)

EXAMPLE 141

[1161]¹H NMR(CDCl₃) : δ1.40 (3H,d), 2.26 (3H,s), 2.39 (3H,s), 3.15 (4H,s), 3.35 (4H,s), 3.97 (3H,s), 5.02 (1H,q), 6.82 (2H,d), 7.06 (2H,d), 7.84 (1H,s)

EXAMPLE 142

[1162]¹H NMR(CDCl₃): δ1.40 (3H,d), 2.39 (3H,s), 3.20 (4H,m), 3.28 (4H,s), 3.98 (3H,s), 5.04 (1H,q), 6.27 (3H,m), 7.85 (1H,s)

EXAMPLE 143

[1163]¹H NMR(CDCl₃) : δ1.45 (3H,d), 2.38 (3H,s), 2.39 (3H,s), 3.02 (4H,m), 3.31 (4H,s), 3.98 (3H,s), 5.07 (1H,q), 7.03 (1H,brs), 7.09 (4H,s), 7.91 (1H,s)

EXAMPLE 144

[1164]¹H NMR(CDCl₃) : δ2.18 (3H,s), 2.27 (6H,s), 2.41 (3H,s), 3.19 (4H,brs), 3.22 (4H,brs), 4.00 (3H,s), 6.55 (2H,s), 6.56 (1H,s), 7.50 (1H,s)

EXAMPLE 145

[1165]¹H NMR(CDCl₃): δ2.18 (3H,s), 2.41 (3H,s), 3.16 (4H,brs), 3.25 (4H,s), 3.76 (6H,s), 4.00 (3H,s), 6.05 (1H,s), 6.03 (2H,s), 7.49 (1H,s)

EXAMPLE 146

[1166]¹H NMR(CDCl₃): δ2.18 (3H,s), 2.40 (3H,s), 3.18 (4H,brs), 3.27 (4H,brs), 4.00 (3H,s), 6.27 (3H,m), 7.50 (1H,s)

EXAMPLE 147

[1167]¹H NMR(CDCl₃) : δ2.18(3H,s), 2.39 (3H,s), 2.40 (3H,s), 3.04 (4H,s), 3.33 (4H,s), 4.01 (3H,s), 7.02 (1H,d), 7.10 (3H,s), 7.50 (4H,s)

EXAMPLE 148

[1168]¹H NMR(CDCl₃) : δ2.10 (3H,s), 2.31 (3H,s), 3.20 (4H,s), 3.37 (4H,s), 3.95 (3H,s), 7.42 (1H,s), 7.96 (2H,s), 8.40 (1H,s)

EXAMPLE 149

[1169]¹H NMR(CDCl₃): δ2.09 (3H,s), 2.26 (3H,s), 2.31 (3H,s), 3.11 (4H,brs), 3.25 (4H,brs), 4.00 (3H,s), 6.80 (2H,d), 7.06 (2H,d), 7.42 (1H,s)

EXAMPLE 150

[1170]¹H NMR(CDCl₃) : δ1.74 (3H,d), 2.28 (9H,s), 3.12 (2H,brs), 3.27 (4H,brs), 3.65 (4H,brs), 4.02 (3H,s), 4.15 (1H,q), 6.54 (3H,s), 8.37 (1H,s)

EXAMPLE 151

[1171]¹H NMR(CDCl₃): δ1.74 (3H,d), 2.28 (3H,s), 3.05 (2H,brs), 3.26 (4H,m), 3.67 (4H,m), 3.82 (6H,s), 4.01 (3H,s), 4.15 (1H,q), 6.06 (1H,s), 6.09 (2H,s), 8.37 (1H,s)

EXAMPLE 152

[1172]¹H NMR(CDCl₃) : δ1.74 (3H,d), 2.28 (3H,s), 3.15 (2H,brs), 3.22 (4H,s), 3.29 (4H,s), 4.00 (3H,s), 4.15 (1H,q), 6.30 (3H,m), 8.37 (1H,s)

EXAMPLE 153

[1173]¹H NMR(CDCl₃) : δ1.74 (3H,d), 2.28 (3H,s), 2.39 (3H,s), 3.10 (2H,brs), 3.04 (4H,s), 3.34 (4H,s), 4.07 (3H,s), 4.15 (1H,q), 7.02 (1H,d), 7.10 (3H,s), 8.37 (1H,s)

EXAMPLE 154

[1174]¹H NMR(CDCl₃): δ1.74 (3H,d), 2.28 (3H,s), 3.07 (2H,brs), 3.20 (4H,s), 3.35 (4H,s), 3.90 (3H,s), 4.15 (1H,q), 7.97 (2H,s), 8.35 (1H,s), 8.42 (1H,s)

EXAMPLE 155

[1175]¹H NMR(CDCl₃): δ1.74 (3H,d), 2.28 (3H,s), 3.11 (2H,brs), 3.20 (8H,s), 4.00 (3H,s), 4.15 (1H,q), 6.17 (1H,s), 6.74 (2H,m), 8.37 (1H,s)

EXAMPLE 156

[1176]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.28 (3H,s), 3.08 (2H,q), 3.17 (4H,s), 3.24 (4H,s), 3.78 (3H,s), 4.07 (3H,s), 6.85 (2H,d), 7.00 (1H,brs), 7.07 (2H,d), 8.05 (1H,s)

EXAMPLE 157

[1177]¹H NMR(CDCl₃): δ1.25 (6H,m), 2.70 (2H,q), 2.95 (4H,t), 3.08 (2H,q), 3.26 (4H,brs), 3.90 (3H,s), 4.07 (3H,s), 7.08 (2H,m), 7.18 (1H,t), 7.24 (1H,d), 8.40 (1H,s)

EXAMPLE 158

[1178]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.27 (6H,s), 3.08 (2H,q), 3.20 (8H,s), 3.79 (3H,s), 4.07 (3H,s), 4.22 (3H,s), 6.56 (1H,s), 6.57 (2H,s), 6.94 (1H,s), 8.38 (1H,s)

EXAMPLE 159

[1179]¹H NMR(CDCl₃) : δ1.26 (3H,t), 3.07 (2H,q), 3.21 (8H,s), 3.77 (6H,s), 3.79 (3H,s), 4.07 (3H,s), 6.05 (1H,s), 6.09 (2H,s), 6.95 (1H,s), 8.37 (1H,s)

EXAMPLE 160

[1180]¹H NMR(CDCl₃) : δ1.27 (3H,t), 3.07 (2H,q), 3.24 (8H,s), 3.81 (3H,s), 4.08 (3H,s), 6.75 (2H,s), 6.83 (1H,s), 7.05 (1H,brs), 8.29 (1H,s)

EXAMPLE 161

[1181]¹H NMR(CDCl₃) : δ1.27 (3H,t), 2.40 (3H,s), 3.07 (6H,m), 3.28 (4H,brs), 3.88 (3H,s), 4.07 (3H,s), 7.05 (2H,m), 7.12 (3H,m), 8.38 (1H,s)

EXAMPLE 162

[1182]¹H NMR(CDCl₃): δ1.27 (3H,t), 1.40 (6H,t), 3.07 (2H,q), 3.26 (4H,s), 3.34 (4H,s), 3.77 (3H,s), 4.08 (3H,s), 4.39 (4H,q), 7.00 (1H,brs), 7.70 (2H,s), 8.17 (1H,s), 8.35 (1H,s)

EXAMPLE 163

[1183]¹H NMR(CDCl₃): δ1.27 (3H,t), 3.07 (2H,q), 3.22 (8H,d), 3.80 (3H,s), 4.08 (3H,s), 6.29 (1H,t), 6.36 (2H,d), 6.99 (1H,brs), 8.32 (1H,s)

EXAMPLE 164

[1184]¹H NMR(CDCl₃): δ1.25 (3H,t), 2.27 (3H,s), 2.69 (2H,q), 3.14 (4H,d), 3.22 (4H,d), 4.01 (3H,s), 4.60 (2H,s), 6.82 (2H,d), 6.96 (1H,brs), 7.06 (2H,d), 7.78 (1H,s)

EXAMPLE 165

[1185]¹H NMR(CDCl₃): δ1.21 (3H,t), 1.26 (3H,t), 2.67 (4H,m), 2.91 (4H,t), 3.27 (4H,s), 4.01 (3H,s), 4.66 (2H,s), 7.06 (2H,m), 7.16 (1H,t), 7.21 (1H,d), 7.82 (1H,s)

EXAMPLE 166

[1186]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.27 (6H,s), 2.69 (2H,q), 3.19 (8H,d), 4.02 (3H,s), 4.60 (2H,s), 6.55 (3H,s), 6.90 (1H,s), 7.80 (1H,s)

EXAMPLE 167

[1187]¹H NMR(CDCl₃) : δ1.26 (3H,t), 2.69 (2H,q), 3.19 (8H,s), 3.76 (6H,s), 4.02 (3H,s), 4.60 (2H,s), 6.03 (1H,s), 6.08 (2H,d), 6.88 (1H,s), 7.79 (1H,s)

EXAMPLE 168

[1188]¹H NMR(CDCl₃): δ1.26 (3H,t), 2.69 (2H,q), 3.20 (8H,s), 4.01 (3H,s), 4.62 (2H,s), 6.73 (2H,s), 6.84 (1H,s), 6.95 (1H,brs), 7.77 (1H,s)

EXAMPLE 169

[1189]¹H NMR(CDCl₃): δ1.26 (3H,t), 2.39 (3H,s), 2.70 (2H,q), 3.03 (4H,d), 3.28 (4H,s), 4.01 (3H,s), 4.65 (2H,s), 7.03 (2H,m), 7.10 (3H,m), 7.80 (1H,s)

EXAMPLE 170

[1190]¹H NMR(CDCl₃): δ1.20 (3H,t), 2.61 (2H,q), 3.09 (4H,s), 3.23 (4H,s), 3.97 (3H,s), 4.45 (4H,s), 4.46 (2H,s), 6.77 (1H,s), 6.81 (2H,s), 6.99 (1H,brs), 7.90 (1H,s)

EXAMPLE 171

[1191]¹H NMR(CDCl₃) : δ1.25 (3H,t), 2.68 (2H,q), 3.21 (4H,s), 3.22 (4H,s), 4.01 (3H,s), 4.62 (2H,s), 6.27 (1H,t), 6.33 (2H,d), 7.05 (1H,brs), 7.76 (1H,s)

EXAMPLE 172

[1192]¹H NMR(CDCl₃) : δ3.24 (8H,s), 3.76 (6H,s), 4.15 (3H,s), 6.00 (1H,s), 6.08 (2H,d), 7.31 (1H,t), 7.35 (1H,s), 7.43 (1H,t), 7.57 (1H,d), 7.71 (1H,d), 8.06 (1H,s)

EXAMPLE 173

[1193]¹H NMR(CDCl₃) : δ2.28 (6H,s), 3.25 (4H,s), 3.26 (4H,s), 4.18 (3H,s), 6.33 (1H,brs), 6.56 (1H,s), 6.58 (2H,d), 7.33 (1H,t), 7.47 (1H,t), 7.57 (1H,d), 7.78 (1H,d), 8.05 (1H,s)

EXAMPLE 174

[1194]¹H NMR(CDCl₃): δ3.26 (8H,s), 4.18 (3H,s), 6.29 (1H,t), 6.36 (2H,d), 7.25 (1H,brs), 7.34 (1H,t), 7.49 (1H,t), 7.50 (1H,d), 7.79 (1H,d), 8.02 (1H,s)

EXAMPLE 175

[1195]¹H NMR(CDCl₃) : δ3.16 (4H,s), 3.36 (4H,s), 3.84 (3H,s), 4.18 (3H,s), 6.86 (1H,d), 6.95 (2H,m), 7.02 (1H,m), 7.34 (1H,t), 7.48 (1H,t), 7.60 (1H,d), 7.78 (1H,d), 8.04 (1H,s)

EXAMPLE 176

[1196]¹H NMR(CDCl₃): δ3.25 (4H,d), 3.32 (4H,s), 4.18 (3H,s), 6.77 (1H,d), 6.85 (2H,m), 7.17 (1H,t), 7.35 (1H,t), 7.50 (1H,t), 7.59 (1H,d), 7.79 (1H,d), 7.99 (1H,s)

EXAMPLE 177

[1197]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.20 (3H,s), 3.18 (4H,d), 3.23 (4H,d), 3.84 (3H,s), 6.65 (1H,s), 6.87 (1H,t), 6.91 (2H,d), 6.93 (1H,brs), 7.25 (2H,m), 7.36 (1H,s)

EXAMPLE 178

[1198]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.20 (3H,s), 2.27 (3H,s), 3.12 (4H,d), 3.22 (4H,d), 3.84 (3H,s), 6.64 (1H,s), 6.83 (2H,d), 6.96 (1H,brs), 7.07 (2H,d), 7.35 (1H,s)

EXAMPLE 179

[1199]¹H NMR(CDCl₃) : δ1.21 (3H,t), 2.20 (3H,s), 2.21 (3H,s), 2.67 (2H,q), 2.90 (4H,t), 3.26 (4H,s), 3.85 (3H,s), 6.65 (1H,s), 7.07 (3H,m), 7.17 (1H,t), 7.21 (1H,d), 7.36 (1H,s)

EXAMPLE 180

[1200]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.20 (3H,s), 2.27 (6H,s), 3.16 (4H,d), 3.20 (4H,d), 3.85 (3H,s), 6.54 (1H,s), 6.56 (2H,s), 6.64 (1H,s), 6.89 (1H,brs), 7.37 (1H,s)

EXAMPLE 181

[1201]¹H NMR(CDCl₃) : δ2.14 (3H,s), 2.20 (3H,s), 3.17 (4H,s), 3.19 (4H,s), 3.77 (6H,s), 3.85 (3H,s), 6.03 (1H,s), 6.08 (2H,d), 6.64 (1H,s), 6.90 (1H,brs), 7.36 (1H,s)

EXAMPLE 182

[1202]¹H NMR(CDCl₃) : δ2.14 (3H,s), 2.20 (3H,s), 3.22 (8H,s), 3.85 (3H,s), 6.28 (1H,t), 6.36 (2H,d), 6.64 (1H,s), 6.89 (1H,brs), 7.36 (1H,s)

EXAMPLE 183

[1203]¹H NMR(CDCl₃) : δ2.15 (3H,s), 2.20 (3H,s), 3.17 (4H,d), 3.21 (4H,d), 3.85 (3H,s), 6.65 (1H,s), 6.78 (1H,d), 6.81 (1H,d), 6.86 (1H,s), 6.94 (1H,brs), 7.16 (1H,t), 7.33 (1H,s)

EXAMPLE 184

[1204]¹H NMR(CDCl₃): δ2.15 (3H,s), 2.20 (3H,s), 3.17 (4H,d), 3.21 (4H,d), 3.85 (3H,s), 6.65 (1H,s), 6.81 (1H,d), 6.96 (2H,brd), 7.02 (1H,s), 7.10 (1H,t), 7.33 (1H,s)

EXAMPLE 185

[1205]¹H NMR(CDCl₃): δ2.19 (3H,s), 2.21 (3H,s), 2.39 (3H,s), 3.00 (4H,d), 3.28 (4H,s), 3.85 (3H,s), 6.64 (1H,s), 6.99 (1H,brs), 7.03 (1H,d), 7.10 (3H,m), 7.36 (1H,s)

EXAMPLE 186

[1206]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.33 (3H,s), 3.19 (4H,s), 3.20 (4H,s), 3.78 (3H,s), 3.98 (3H,s), 6.84 (1H,s), 6.87 (1H,t), 6.93 (2H,m), 7.24 (1H,d), 7.56 (1H,s)

EXAMPLE 187

[1207]¹H NMR(CDCl₃) : δ2.13 (3H,s), 2.27 (3H,s), 2.32 (3H,s), 3.13 (4H,d), 3.19 (4H,d), 3.77 (3H,s), 3.98 (3H,s), 6.81 (1H,s), 6.83 (2H,d), 7.07 (2H,d), 7.54 (1H,s)

EXAMPLE 188

[1208]¹H NMR(CDCl₃): δ2.13 (3H,s), 2.28 (9H,s), 3.17 (4H,brs), 3.78 (3H,s), 3.98 (3H,s), 6.56 (3H,s), 6.70 (1H,s), 7.53 (1H,s)

EXAMPLE 189

[1209]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.32 (3H,s), 3.17 (8H,s), 3.77 (9H,s), 3.98 (3H,s), 6.04 (1H,s), 6.08 (2H,s), 6.81 (1H,s), 7.53 (1H,s)

EXAMPLE 190

[1210]¹H NMR(CDCl₃): δ2.15 (3H,s), 2.33 (3H,s), 3.17 (8H,s), 3.78 (3H,s), 3.98 (3H,s), 6.28 (1H,t), 6.35 (2H,d), 6.78 (1H,s), 7.50 (1H,s)

EXAMPLE 191

[1211]¹H NMR(CDCl₃) : δ2.15 (3H,s), 2.34 (3H,s), 2.38 (3H,s), 3.00 (4H,s), 3.28 (4H,s), 3.78 (3H,s), 3.90 (3H,s), 7.01 (1H,s), 7.10 (3H,s), 7.55 (1H,s)

EXAMPLE 192

[1212]¹H NMR(CDCl3): δ2.16 (3H,s), 2.34 (3H,s), 3.20 (4H,s), 3.37 (4H,s), 3.78 (3H,s), 3.90 (3H,s), 6.78 (1H,s), 7.47 (1H,s), 7.97 (2H,s), 8.42 (1H,s)

EXAMPLE 193

[1213]¹H NMR(CDCl₃) : δ1.15 (3H,t), 2.37 (3H,s), 2.50 (2H,q), 3.18 (4H,brs), 3.23 (4H,brs), 3.82 (3H,s), 3.97 (3H,s), 6.72 (2H,s), 6.88 (1H,s), 7.45 (1H,s)

EXAMPLE 194

[1214]¹H NMR(CDCl₃) : δ1.26 (3H,t), 3.07 (2H,q), 3.22 (8H,s), 3.79 (3H,s), 3.86 (3H,s), 4.07 (3H,s), 6.29 (1H,t), 6.36 (2H,d), 8.29 (1H,s)

EXAMPLE 195

[1215]¹H NMR(CDCl₃) : δ1.26 (3H,t), 1.40 (6H,t), 3.06 (2H,q), 3.27 (4H,brs), 3.38 (4H,brs), 3.77 (3H,s), 3.81 (3H,s), 4.07 (3H,s), 4.38 (4H,q), 7.76 (2H,s), 8.17 (1H,s), 8.30 (1H,s)

EXAMPLE 196

[1216]¹H NMR(CDCl₃) : δ1.24 (3H,t), 2.67 (2H,q), 3.21 (8H,s), 3.78 (3H,s), 4.01 (3H,s), 4.59 (2H,s), 4.63 (4H,s), 6.84 (2H,m), 6.88 (2H,s), 7.78 (1H,s)

EXAMPLE 197

[1217]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.20 (3H,s), 2.27 (3H,s), 3.13 (4H,brs), 3.24 (4H,brs), 3.78 (3H,s), 3.84 (3H,s), 6.64 (1H,s), 6.84 (2H,brs), 7.07 (2H,d), 7.27 (1H,brs)

EXAMPLE 198

[1218]¹H NMR(CDCl₃): δ2.14 (3H,s), 2.20 (3H,s), 2.25 (6H,s), 3.16 (4H,brs), 3.22 (4H,brs), 3.79 (3H,s), 3.83 (3H,s), 6.54 (2H,s), 6.64 (1H,s), 6.81 (1H,brs), 7.27 (1H,brs)

EXAMPLE 199

[1219]¹H NMR(CDCl₃) : δ2.11 (3H,brs), 2.16 (3H,s), 2.36 (3H,s), 3.24 (4H,t), 3.80 (4H,s), 3.92 (3H,s), 6.85 (1H,brs), 6.89 (1H,t), 6.95 (2H,d), 7.28 (2H,t)

EXAMPLE 200

[1220]¹H NMR(CDCl₃) : δ2.11 (3H,brs), 2.16 (3H,s), 2.28 (3H,s), 2.36 (3H,s), 3.19 (4H,t), 3.80 (4H,brs), 3.92 (3H,s), 6.86 (3H,brd), 7.08 (2H,d)

EXAMPLE 201

[1221]¹H NMR(CDCl₃) : δ0.92 (3H,t), 1.35 (2H,m), 1.55 (2H,m), 2.10 (3H,brs), 2.16 (3H,s), 2.36 (3H,s), 2.54 (2H,t), 3.20 (4H,t), 3.80 (4H,brs), 3.92 (3H,s), 6.87 (3H,brd), 7.09 (2H,d)

EXAMPLE 202

[1222]¹H NMR(CDCl₃): δ2.10 (3H,brs), 2.16 (3H,s), 2.89 (6H,s), 2.36 (3H,s), 3.21 (4H,t), 3.78 (4H,brs), 3.92 (3H,s), 6.56 (1H,s), 6.59 (2H,s), 6.84 (3H,brs)

EXAMPLE 203

[1223]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 2.16 (3H,s), 2.36 (3H,s), 3.22 (4H,t), 3.79 (7H,brs), 3.92 (3H,s), 6.84 (1H,brs), 6.95 (4H,s)

EXAMPLE 204

[1224]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 2.16 (3H,s), 2.36 (3H,s), 3.24 (4H,brs), 3.78 (1OH,s), 3.92 (3H,s), 6.05 (1H,s), 6.11 (2H,s), 6.84 (3H,brs)

EXAMPLE 205

[1225]¹ H NMR(CDCl₃): δ2.10 (3H,brs), 2.16 (3H,s), 2.36 (3H,s), 3.24 (4H,t), 3.78 (4H,t), 6.28 (1H,t), 6.39 (2H,d), 6.84 (1H,s)

EXAMPLE 206

[1226]¹H NMR(CDCl₃): δ2.10 (3H,s), 2.16 (3H,s), 2.36 (3H,s), 3.25 (4H,t), 3.78 (4H,t), 3.92 (3H,s), 6.77 (2H,s), 6.84 (2H,s)

EXAMPLE 207

[1227]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 2.17 (3H,s), 2.36 (3H,s), 3.25 (4H,brs), 3.79 (4H,brs), 3.92 (3H,s), 6.84 (2H,m), 7.00 (1H,d), 7.06 (1H,brs), 7.13 (1H,t)

EXAMPLE 208

[1228]¹H NMR(CDCl₃): δ2.12 (3H,s), 2.17 (3H,s), 2.37 (3H,s), 3.50 (4H,t), 3.88 (4H,brs), 3.93 (3H,s), 6.87 (1H,brs), 8.00 (2H,d), 8.43 (1H,s)

EXAMPLE 209

[1229]¹H NMR(CDCl₃): δ1.41 (6H,t), 2.11 (3H,brs), 2.15 (3H,s), 2.37 (3H,s), 3.36 (4H,brs), 3.83 (4H,brs), 3.92 (3H,s), 4.40 (4H,q), 6.85 (1H,brs), 7.78 (2H,s), 8.18 (1H,s)

EXAMPLE 210

[1230]¹H NMR(CDCl₃): δ1.67 (3H,t), 2.10 (3H,s), 2.39 (3H,s), 2.51 (2H,q), 3.25 (4H,t), 3.80 (4H,t), 3.92 (3H,s), 6.90 (2H,t), 6.95 (2H,d), 7.29 (2H,t)

EXAMPLE 211

[1231]¹H NMR(CDCl₃): δ1.17 (3H,t), 2.10 (3H,brs), 2.39 (3H,s), 2.52 (2H,q), 3.13 (4H,brs), 3.84 (4H,brs), 3.88 (3H,s), 3.93 (3H,s), 6.89 (2H,brd), 6.93 (2H,m), 7.04 (1H,m)

EXAMPLE 212

[1232]¹H NMR(CDCl₃): δ1.16 (3H,t), 2.09 (3H,s), 2.39 (3H,s), 2.51 (2H,q), 3.23 (4H,t), 3.79 (10H,s), 3.92 (3H,s), 6.05 (1H,s), 6.11 (2H,d), 6.87 (1H,s)

EXAMPLE 213

[1233]¹H NMR(CDCl₃) : δ1.18 (3H,t), 1.25 (3H,t), 2.11 (3H,brs), 2.40 (3H,s), 2.52 (2H,q), 2.72 (2H,q), 2.96 (4H,brs), 3.79 (4H,brs), 3.94 (3H,s), 6.88 (1H,brs), 7.09 (2H,m), 7.18 (1H,t), 7.24 (1H,d)

EXAMPLE 214

[1234]¹H NMR(CDCl₃) : δ1.16 (3H,t), 2.09 (3H,s), 2.29 (6 H,s), 2.39(3 H,s), 2.51(2 H,q), 3.22(4 H,t), 3.78(4 H,t), 3.92(3H,s), 6.56 (1H,s), 6.59 (2H,s), 6.87 (1H,s)

EXAMPLE 215

[1235]¹H NMR(CDCl₃): δ1.16 (3H,t), 2.11 (3H,brs), 2.40 (3H,s), 2.51 (2H,q), 3.27 (4H,s), 3.80 (4H,s), 3.92 (3H,s), 6.28 (1H,t), 6.39 (2H,d), 6.84 (1H,s)

EXAMPLE 216

[1236]¹H NMR(CDCl₃): δ1.17 (3H,t), 2.12 (3H,brs), 2.40 (3H,s), 2.52 (2H,q), 3.27 (4H,s), 3.80 (4H,s), 3.92 (3H,s), 6.77 (2H,d), 6.84 (1H,s), 6.90 (1H,brs)

EXAMPLE 217

[1237]¹H NMR(CDCl₃): δ1.15 (3H,t), 2.03 (3H,brs), 2.38 (3H,s), 2.50 (2H,q), 2.90 (4H,brs), 3.51 (4H,brs), 3.90 (3H,s), 6.82 (1H,d), 7.03 (1H,d), 7.10 (1H,t), 7.27 (3H,m), 7.39 (2H,t), 7.61 (2H,d)

EXAMPLE 218

[1238]¹H NMR(CDCl₃) : δ1.15 (3H,t), 2.13 (3H,brs), 2.41 (3H,s), 2.52 (2H,q), 3.52 (4H,brs), 3.93 (7H,s), 6.87 (1H,brs), 7.99 (2H,d), 8.44 (1H,s)

EXAMPLE 219

[1239]¹H NMR(CDCl₃): δ1.17(3H,t), 2.10 (3H,brs), 2.39 (3H,s), 2.42 (3H,s), 2.52 (2H,q), 3.06 (4H,s), 3.83 (4H,s), 3.93 (3H,s), 6.88 (1H,brs), 7.05 (1H,m), 7.12 (3H,s)

EXAMPLE 220

[1240]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 2.73 (3H,s), 3.23 (4H,brs), 3.86 (1OH,s), 3.89 (3H,s), 6.05 (1H,s), 6.11 (2H,s), 7.62 (1H,brs)

EXAMPLE 221

[1241]¹H NMR(CDCl₃) δ2.10 (3H,brs), 2.29 (6H,s), 2.73 (3H,s), 3.23 (4H,brs), 3.82 (4H,brs), 3.86 (3H,s), 3.99 (3H,s), 6.57 (3H,m), 7.62 (1H,brs)

EXAMPLE 222

[1242]¹H NMR(CDCl₃): δ2.10 (3H,s), 2.73 (3H,s), 3.27 (4H,t), 3.83 (4H,s), 3.86 (3H,s), 4.00 (3H,s), 6.30 (1H,t), 6.40 (2H,d), 7.64 (1H,brs)

EXAMPLE 223

[1243]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 2.73 (3H,s), 3.14 (4H,brs), 3.86 (7H,s), 3.89 (3H,s), 4.00 (3H,s), 6.89 (1H,d), 6.95 (2H,m), 7.04 (1H,brm), 7.62 (1H,brs)

EXAMPLE 224

[1244]¹H NMR(CDCl₃) : δ2.11 (3H,brs), 2.73 (3H,s), 3.26 (4H,t), 3.85 (7H,s), 4.00 (3H,s), 6.91 (1H,t), 6.95 (2H,d), 7.30 (2H,t), 7.63 (1H,brs)

EXAMPLE 225

[1245]¹H NMR(CDCl₃) : δ2.10 (3H,s), 2.27 (3H,s), 2.72 (3H,s), 3.20 (4H,t), 3.83 (4H,s), 3.85 (3H,s), 4.00 (3H,s), 6.87 (2H,d), 7.09 (3H,d), 7.63 (1H,brs)

EXAMPLE 226

[1246]¹H NMR(CDCl₃): δ2.11 (3H,brs), 2.73 (3H,s), 3.27 (4H,brs), 3.86 (7H,s), 4.00 (3H,s), 6.81 (1H,d), 6.85 (1H,d), 6.90 (1H,s), 7.19 (1H,t), 7.63 (1H,brs)

EXAMPLE 227

[1247]¹H NMR(CDCl₃) : δ2.12 (3H,brs), 2.29 (6H,s), 2.53 (3H,s), 2.67 (3H,s), 3.24 (4H,brs), 3.83 (4H,brs), 4.00 (3H,s), 6.58 (1H,s), 6.60 (2H,s), 7.47 (1H,brs)

EXAMPLE 228

[1248]¹H NMR(CDCl₃) : δ2.12 (3H,brs), 2.53 (3H,s), 2.68 (3H,s), 3.25 (4H,t), 3.79 (6H,s), 3.82 (4H,brs), 4.00 (3H,s), 6.06 (1H,s), 6.12 (2H,d), 7.46 (1H,brs)

EXAMPLE 229

[1249]¹H NMR(CDCl₃): δ2.12 (3H,s), 2.53 (3H,s), 2.68 (3H,s), 3.26 (4H,t), 3.77 (4H,t), 4.00 (3H,s), 6.89 (3H,d), 7.19 (2H,d), 7.46 (1H,s)

EXAMPLE 230

[1250]¹H NMR(CDCl₃) : δ2.12 (3H,brs), 2.12 (3H,s), 2.53 (3H,s), 2.68 (3H,s), 3.22 (4H,s), 3.85 (3H,brs), 4.00 (3H,s), 6.87 (2H,d), 7.10 (2H,d), 7.45 (1H,s)

EXAMPLE 231

[1251]¹H NMR(CDCl₃) : δ2.12 (3H,s), 2.55 (3H,s), 2.68 (3H,s), 3.32 (4H,brs), 3.86 (4H,brs), 4.01 (3H,s), 6.38 (3H,m), 7.47 (1H,brs)

EXAMPLE 232

[1252]¹H NMR(CDCl₃) : δ2.12 (3H,s), 2.43 (3H,s), 2.54 (3H,s), 2.68 (3H,s), 3.07 (4H,brs), 3.86 (4H,brs), 4.00 (3H,s), 7.06 (1H,m), 7.13 (3H,m), 7.46 (1H,brs)

EXAMPLE 233

[1253]¹H NMR(CDCl₃) δ1.28 (3H,t), 2.13 (3H,brs), 2.29 (3H,s), 3.11 (2H,q), 3.21 (4H,brs), 3.85 (7H,brs), 4.00 (3H,s), 6.89 (2H,brs), 7.08 (2H,d), 7.62 (1H,brs)

EXAMPLE 234

[1254]¹H NMR(CDCl₃) : δ1.24 (3H,t), 1.28 (3H,t), 2.12 (3H,brs), 2.72 (2H,q), 2.96 (4H,brs), 3.10 (2H,q), 3.81 (4H,brs), 3.86 (3H,s), 4.00 (3H,s), 7.09 (2H,m), 7.19 (1H,t), 7.24 (1H,d), 7.60 (1H,brs)

EXAMPLE 235

[1255]¹H NMR(CDCl₃): δ1.28 (3H,t), 2.10 (3H,brs), 2.29 (6H,s), 3.11 (2H,q), 3.23 (4H,brs), 3.82 (4H,brs), 3.85 (3H,s), 4.00 (3H,s), 6.57 (1H,s), 6.59 (2H,s), 7.59 (1H,brs)

EXAMPLE 236

[1256]¹H NMR(CDCl₃): δ1.28 (3H,t), 2.10 (3H,brs), 3.10 (2H,q), 3.24 (4H,brs), 3.79 (6H,s), 3.81 (4H,brs), 3.85 (3H,s), 4.00 (3H,s), 6.06 (1H,s), 6.11 (2H,s), 7.59 (1H,brs)

EXAMPLE 237

[1257]¹H NMR(CDCl₃) : δ1.28 (3H,t), 2.10 (3H,brs), 3.11 (2H,q), 3.28 (4H,brs), 3.82 (4H,brs), 3.85 (3H,s), 4.00 (3H,s), 6.77 (2H,d), 6.85 (1H,s), 7.60 (1H,brs)

EXAMPLE 238

[1258]¹H NMR(CDCl₃): δ1.28 (3H,t), 2.10 (3H,brs), 2.43 (3H,s), 3.06 (6H,m), 3.86 (7H,brs), 4.01 (3H,s), 7.06 (1H,s), 7.12 (3H,s), 7.60 (1H,brs)

EXAMPLE 239

[1259]¹H NMR(CDCl₃) : δ1.28 (3H,t), 1.43 (6H,t), 2.11 (3H,brs), 3.12 (2H,q), 3.37 (4H,brs), 3.86 (7H,s), 4.01 (3H,s), 4.41 (4H,q), 7.60 (1H,brs), 7.79 (2H,s), 8.18 (1H,s)

EXAMPLE 240

[1260]¹H NMR(CDCl₃) : δ1.28 (3H,t), 2.10 (3H,brs), 3.10 (2H,q), 3.28 (4H,brs), 3.82 (4H,brs), 3.86 (3H,s), 4.00 (3H,s), 6.30 (1H,t), 6.39 (2H,d), 7.60 (1H,brs)

EXAMPLE 241

[1261]¹H NMR(CDCl₃) : δ2.07 (3H,s), 3.27 (4H,t), 3.79 (6H,s), 3.86 (4H,t), 4.10 (3H,s), 6.06 (1H,m), 6.12 (2H,d), 7.32 (1H,t), 7.36 (1H,s), 7.48 (1H,t), 7.61 (1H,d), 7.80 (1H,d)

EXAMPLE 242

[1262]¹H NMR(CDCl₃) : δ2.07 (3H,s), 2.30 (6H,s), 3.25 (4H,s), 3.86 (4H,s), 4.10 (3H,s), 6.58 (1H,s), 6.60 (2H,s), 7.32 (1H,t), 7.36 (1H,s), 7.49 (1H,d), 7.80 (1H,d)

EXAMPLE 243

[1263]¹H NMR(CDCl₃): δ2.09 (3H,brs), 3.27 (4H,s), 3.87 (4H,s), 4.10 (3H,s), 6.29 (1H,t), 6.39 (2H,d), 7.32 (1H,t), 7.37 (1H,s), 7.49 (1H,t), 7.80 (1H,d)

EXAMPLE 244

[1264]¹H NMR(CDCl₃): δ2.09 (3H,brs), 3.15 (4H,t), 3.89 (4H,s), 4.11 (3H,s), 6.89 (1H,d), 6.96 (2H,m), 7.04 (1H,m), 7.32 (1H,t), 7.38 (1H,brs), 7.48 (1H,t), 7.62 (1H,d), 7.80 (1H,d)

EXAMPLE 245

[1265]¹H NMR(CDCl₃) : δ2.10 (3H,brs), 3.29 (4H,t), 3.88 (4H,brs), 4.10 (3H,s), 6.82 (1H,dd), 6.88 (1H,d), 6.92 (1H,s), 7.20 (1H,t), 7.33 (1H,t), 7.40 (1H,brs), 7.49 (1H,t), 7.62 (1H,d), 7.80 (1H,d)

EXAMPLE 246

[1266]¹H NMR(CDCl₃): δ2.14 (3H,brs), 2.17 (3H,s), 2.22 (3H,s), 3.25 (4H,t), 3.78 (7H,s), 6.60 (1H,brs), 6.66 (1H,s), 6.89 (1H,t), 6.95 (2H,t), 7.29 (2H,t)

EXAMPLE 247

[1267]¹H NMR(CDCl₃): δ2.14 (3H,brs), 2.17 (3H,s), 2.22 (3H,s), 2.28 (3H,s), 3.19 (4H,t), 3.77 (7H,s), 6.60 (1H,brs), 6.66 (1H,s), 6.86 (2H,d), 7.08 (2H,d)

EXAMPLE 248

[1268]¹H NMR(CDCl₃): δ1.25 (3H,t), 2.14 (3H,brs), 2.18 (3H,s), 2.23 (3H,s), 2.72 (2H,q), 2.96 (4H,brs), 3.75 (4H,brs), 3.79 (3H,s), 6.60 (1H,brs), 6.67 (1H,s), 7.08 (2H,t), 7.18 (1H,t), 7.24 (1H,m)

EXAMPLE 249

[1269]¹H NMR(CDCl₃) : δ2.12 (3H,s), 2.16 (3H,s), 2.22 (3H,s), 2.29 (6H,s), 3.21 (4H,t), 3.74 (4H,t), 3.77 (3H,s), 6.55 (1H,s), 6.59 (3H,s), 6.65 ( 1H,s)

EXAMPLE 250

[1270]¹H NMR(CDCl₃): δ2.12 (3H,s), 2.16 (3H,s), 2.22 (3H,s), 3.23 (4H,t), 3.74 (4H,t), 3.77 (3H,s), 3.78 (6H,s), 6.04 (1H,s), 6.12 (2H,d), 6.59 (1H,s), 6.65 (1H,s)

EXAMPLE 251

[1271]¹H NMR(CDCl₃): δ2.11 (3H,s), 2.16 (3H,s), 2.22 (3H,s), 3.25 (4H,t), 3.74 (4H,t), 3.77 (3H,s), 6.28 (1H,t), 6.39 (2H,d), 6.59 (1H,s), 6.66 (1H,s)

EXAMPLE 252

[1272]¹H NMR(CDCl₃) : δ2.14 (3H,brs), 2.17 (3H,s), 2.22 (3H,s), 3.25 (4H,t), 3.76 (4H,brs), 3.78 (3H,s), 6.61 (1H,brs), 6.66 (1H,s), 6.83 (2H,m), 6.90 (1H,s), 7.18 (1H,t)

EXAMPLE 253

[1273]¹H NMR(CDCl₃) : δ2.14 (3H,brs), 2.17 (3H,s), 2.23 (3H,s), 3.25 (4H,t), 3.78 (7H,s), 6.61 (1H,brs), 6.66 (1H,s), 6.85 (1H,d), 6.98 (1H,d), 7.06 (1H,s), 7.12 (1H,t)

EXAMPLE 254

[1274]¹H NMR(CDCl₃) δ2.14 (3H,brs), 2.17 (3H,s), 2.22 (3H,s), 2.42 (3H,s), 3.06 (4H,t), 3.78 (7H,s), 6.60 (1H,brs), 6.66 (1H,s), 7.06 (1 H,m), 7.12 (3H,s)

[1275] Antitumor activities of the compounds of the present invention were tested in vitro against 5 kinds of human tumor cell lines and a leukemia tumor cell line. The method and result of the in vitro tests is as follows.

Experimental 1

[1276] In vitro antitumor effect against human tumor cell lines.

[1277] A. Tumor Cell Line:

[1278] A549 (human non-small lung cell)

[1279] SKOV-3 (human ovarian)

[1280] HCT-15 (human colon)

[1281] XF 498 (human CNS)

[1282] SKMEL-2 (human melanoma)

[1283] B. SRB Assay Method.

[1284] a. Human solid tumor cell lines, A549(non-small lung cell), SKMEL-2(melanoma), HCT-15(colon), SKOV-3(ovarian), XF-498(CNS) were cultured at 37° C. in 5% CO₂ incubators using RPMI 1640 media containing 10% FBS, while they were transfer-cultured successively once or twice per week. Cell cultures were dissolved in a solution of 0.25% trypsin and 3 mM CDTA PBS(−) and then cells were separated from media which the cells were sticked on.

[1285] b. 5×10³˜10⁴ cells were added into each well of 96-well plate and cultured in 5% CO₂ incubator, at 37° C., for 24 hours.

[1286] c. Each sample drug was dissolved in a little DMSO and diluted with the used medium to a prescribed concentration for experiments, wherein the final concentration of DMSO was controlled below 0.5%.

[1287] d. Medium of each well cultured for 24 hours as above b. was removed by aspiration. Each 200 μl of drug samples prepared in c. was added into each well and the wells were cultured for 48 hours. Tz(time zero) plates were collected at the point of time drugs were added.

[1288] e. According to the SRB assay method, cell fixing with TCA, staining with 0.4% SRB solution, washing with 1% acetic acid and elution of dye with 10 mM Tris solution were carried out on Tz plates and culture-ended plates, whereby OD values were measured at 520 nm.

[1289] C. Calculation of Result

[1290] a. Time zero(Tz) value was determined with measuring the SRB protein amounts of the Tz plates collected at the point of time drugs were added.

[1291] b. Control value (C) was determined with the OD values of wells untreated with a drug.

[1292] c. Drug-treated test value(T) was determined with the OD values of drug-treated wells.

[1293] d. Effects of drugs were estimated with growth stimulation, net growth inhibition, net killing etc., being calculated from Tz, C and T.

[1294] e. If T≧Tz, cellular response function was calculated by 100×(T−Tz)/(C−Tz), and if T<Tz, by 100×(T−Tz)/Tz. The results are shown in the next table 1.

REFERENCE

[1295] 1) P. Skehan, R. Strong, D Scudiero, A. Monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenny and M. R. Boyd : Proc. Am. Assoc. Cancer Res., 30, 612(1989)

[1296] 2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks and M. R. boyd.; J. Natl. Cancer Inst., 82, 1113(1990)

[1297] 3) P. Skehan, R. Strong, D. Scudiero, A. monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenny and M. R. Boyd.;J, Natl. Cancer Ins., 82, 1107(1990)

[1298] D. Results.

[1299] It was found that all the tested compounds of the present invention have superior antitumor activities to the control, cisplatin. TABLE 1 ED₅₀ = μg/ml Example No. A 549 SK-OV-3 SK-MEL-2 XF-498 HCT 15 2 0.032 0.088 0.029 0.084 0.019 3 0.0016 0.0064 0.0015 0.0022 0.0020 4 0.047 0.251 0.042 0.089 0.038 7 0.0024 0.0072 0.0023 0.0027 0.0028 12 0.008 0.069 0.008 0.017 0.001 14 0.204 0.677 0.283 0.340 0.067 15 0.079 0.184 0.038 0.096 0.071 19 0.0064 0.143 0.043 0.093 0.080 20 0.323 0.904 0.211 0.970 0.295 21 0.038 0.093 0.024 0.097 0.008 28 0.0001 0.0006 <0.0001 0.0001 0.0001 30 0.0006 0.0007 <0.0001 0.0005 0.0007 34 0.0023 0.0038 0.0003 0.0021 0.0021 35 0.0001 0.0007 <0.0001 0.0001 0.0001 37 0.01 0.02 0.02 0.003 0.009 38 0.00003 0.00009 0.00004 0.00011 0.00013 39 0.10 0.33 0.07 0.14 0.06 40 0.41 1.01 0.37 0.81 0.39 42 0.0018 0.0043 0.0012 0.0057 0.0026 45 0.0001 0.0002 <0.0001 0.0002 0.0001 46 0.002 0.007 0.003 0.001 0.002 48 0.001 0.007 0.0003 0.004 0.002 51 0.37 0.68 0.28 0.63 0.18 53 0.17 0.21 0.93 0.27 0.05 55 0.34 0.49 0.22 0.41 0.33 64 0.019 0.057 0.011 0.014 0.032 66 0.005 0.008 0.002 0.008 0.003 68 0.38 0.86 0.34 0.47 0.31 72 0.0001 0.0007 <0.0001 0.0001 0.0001 74 0.0020 0.038 0.003 0.024 0.028 86 0.04 0.08 0.03 0.04 0.06 87 0.01 0.03 0.66 0.08 0.008 89 0.04 0.20 0.03 0.04 0.05 90 0.38 0.35 0.90 0.68 0.20 99 0.012 0.008 0.006 0.010 0.003 101 0.0003 0.0003 0.0003 0.0002 0.0001 107 0.032 0.013 0.005 0.008 0.009 118 0.057 0.032 0.019 0.017 0.0002 120 0.64 0.73 0.28 0.82 0.30 125 0.0009 0.0008 0.0001 0.0001 0.0001 127 0.013 0.011 0.005 0.006 0.002 132 0.011 0.007 0.001 0.002 0.001 133 0.0001 0.0001 0.0001 0.0001 0.0001 138 0.074 0.030 0.016 0.018 0.006 139 0.0007 0.0007 0.0002 0.0003 0.0004 159 0.029 0.010 0.002 0.006 0.0006 172 0.07 0.08 0.02 0.03 0.02 173 0.40 0.86 0.15 0.21 0.18 176 0.0012 0.0009 0.0003 0.0001 0.0001 177 0.0006 0.0008 0.0003 0.0004 0.0001 180 0.28 0.16 0.31 0.24 0.16 181 0.13 0.06 0.11 0.04 0.02 182 0.292 0.081 0.033 0.103 0.006 Cisplatin 0.91 1.32 0.87 0.77 3.17

Experimental 2

[1300] In vitro antitumor effects against animal leukemia cells.

[1301] A. Material:

[1302] Tumor cell line: P388 (mouse lymphoid neoplasma cell)

[1303] B. Method:

[1304] Dye Exclusion Assay.

[1305] 1) Concentrations of P388 cells being cultured in RPMI 1640 media containing 10% FBS were regulated to 1×10⁶ cells/ml.

[1306] 2) Sample drugs of respective concentrations diluted in the ratio of log doses were added into each cell culture and cultured at 37° C., for 48 hours, in 50% CO₂ incubator, and then viable cell numbers were measured by dye exclusion test using trypan blue.

[1307] 3) Concentrations of sample compounds showing 50 % cell growth inhibition compared with the control(ICso) were determined and listed in the table 2 below.

REFERENCE

[1308] 1) P. Skehan, R. Strong, D. Scudiero, A. Monks, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesh, S. Kenney and M. R. Boyd.: Proc. Am. Assoc. Cancer Res., 30, 612(1989).

[1309] 2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks, J. Natl. Cancer Inst., 82, 1113(1990)

[1310] 3) P. Skehan, R. Strong, D. Scudiero, J. B. Mcmahan, D. T. Vistica, J. Warren, H. Bokesch, S. Kenney and M. R. Boyd.: J. Natl. Cancer Inst., 82, 1107(1990)

[1311] C. Results

[1312] As the results of measurement of antitumor activities of compounds of the present invention against P388 mouse leukemia cells, it was found that all the compounds tested have equal to or higher antitumor activities than those of the control drug, mitomycin C. Example No. P388 2 0.3 3 0.01 7 0.02 11 0.02 12 0.1 15 0.70 19 0.2 20 1.2 21 0.8 28 0.04 30 0.07 34 0.14 35 0.01 37 0.3 38 0.01 42 0.03 45 0.15 46 0.2 48 0.39 64 0.34 66 0.2 72 0.10 74 0.68 99 0.04 101 0.002 107 0.04 118 0.3 138 0.1 139 0.03 173 0.4 180 0.05 181 0.03 182 0.2 Mitomycin C 1.1

Experimental 3

[1313] Acute toxicity test (LD₅₀):

[1314] A. Method:

[1315] Litchfield-Wilcoxon method.

[1316] 6 weeks old ICR mice (male 30±2.0 g) were fed freely with solid feed and water at room temperature, 23±11° C. at humidity 60±5%. Sample drugs were injected into abdominal cavities of mice, while each group comprises 6 mice. Observed during 14 days, external appearances and life or death were recorded, and then, visible pathogenies were observed from dead animals by dissection. LD₅₀ value was calculated by

[1317] Litchfiled-wilcoxon method.

[1318] B. Result

[1319] The results are shown at the next table 3. TABLE 3 LD₅₀(mg/kg) Example No. p.o. i.v. i.p. 7 75 38 410 97 99 >200 104 212 Cisplatin 9.7

[1320] As described above, it was found that the compounds of the present invention are more safer than cisplatin, whereby the present compounds may solve problems of known drugs by the prior art such as restriction of dosage, toxicity, etc. 

What is claimed:
 1. A compound of the general formula(I)

wherein R₁ and R₂ are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy, C₁-C₄ hydroxyalkyl, C₁-C₄ aminoalkyl or C₁-C₄ hydroxyirinoalkyl, or R₁ and R₂ are fused to form C₃-C₄ unsaturated ring; R₃, R₄, R₅, R₆ and R₇ are independently hydrogen, halogen, hydroxy, nitro, amino, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy or C₁-C₄ thioalkoxy; R₈ is C₁-C₄ alkyl; Y is oxygen, sulphur, amino, substituted amino or C₁-C₄ thioalkyl; Z is C₁-C₄ alkoxy, C₁-C₄ alkyl, C₁-C₄ alkylamino or C₁-C₄ thioalkoxy; X₁ and X₂ are independently carbon or nitrogen; and —N═C— and —C═Y— may form a single bond or a double bond provided that if —N═C— forms a single bond, —C═Y— forms a double bond, and if —C═Y— forms a single bond, —N═C— forms a double bond and R₈ is nonexistent; or pharmaceutically acceptable acid addition salts thereof.
 2. A process for the preparation of compound of the general formula (Ia) or a pharmaceutically acceptable acid addition salt thereof comprising reacting a compound of the general formula (2) with a —C(═Y)— group-providing agent in a conventional organic solvent to obtain a compound of the general formula (3) and successively reacting the compound of the general formula (3) with a compound of the general formula (4) to give the compound of the general formula (5), and reacting the compound of the formula (5) with an alkylating agent or arylating agent in the presence of a base to give the compound of the general formula (Ia).

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, X₁, X₂, Y and Z are as defined above, and Lie is a conventional leaving group.
 3. A process for the preparation of compound of the general formula (Ib) comprising reacting a compound of the general formula (II) with an alkylating agent in the presence of a base to give a compound of the general formula (I′) and reacting the compound of the formula (I′) with a substituted or unsubstitued amine in the presence of a base to give a compound of the general formula (Ib).

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, Xi, X₂, Y and Z are as defined above, and R′ is C₁-C₄ alkyl. 